Wellcome Trust MRC Cambridge Stem Cell Institute
Lead Research Organisation:
University of Cambridge
Department Name: UNLISTED
Abstract
Wellcome Trust MRC Cambridge Stem Cell Institute
Director: Professor Austin Smith, University of Cambridge
Stem cell science is providing a stream of new knowledge about how our bodies are made and maintained. This research brings the promise that better understanding of stem cells will lead to future medical applications. Treatments may come through several routes. First, human stem cells grown in the laboratory can be used to produce experimental models of diseased tissues and to test therapeutic drugs. Second, some disorders, including forms of cancer, involve abnormal behaviour of stem cells. As we learn how to control stem cells it may become possible to correct these faults. Third, finding how to prevent a decline in numbers and activity of stem cells may help to maintain health during ageing. Finally, stem cells could be used to renew damaged tissues and replace missing cells in certain disorders.
The Cambridge Stem Cell Institute is being formed to explore and define the properties of stem cells and establish their true medical potential. Leading research scientists, technology specialists and doctors will work side by side to create a world-leading centre of excellence in stem cell biology and medicine. The Institute will also collaborate with bioindustry and will provide high level training for young researchers from around the world.
Director: Professor Austin Smith, University of Cambridge
Stem cell science is providing a stream of new knowledge about how our bodies are made and maintained. This research brings the promise that better understanding of stem cells will lead to future medical applications. Treatments may come through several routes. First, human stem cells grown in the laboratory can be used to produce experimental models of diseased tissues and to test therapeutic drugs. Second, some disorders, including forms of cancer, involve abnormal behaviour of stem cells. As we learn how to control stem cells it may become possible to correct these faults. Third, finding how to prevent a decline in numbers and activity of stem cells may help to maintain health during ageing. Finally, stem cells could be used to renew damaged tissues and replace missing cells in certain disorders.
The Cambridge Stem Cell Institute is being formed to explore and define the properties of stem cells and establish their true medical potential. Leading research scientists, technology specialists and doctors will work side by side to create a world-leading centre of excellence in stem cell biology and medicine. The Institute will also collaborate with bioindustry and will provide high level training for young researchers from around the world.
Technical Summary
This award is to facilitate creation of a world-leading centre for fundamental and translational stem cell research at the University of Cambridge. The Cambridge Stem Cell Institute (SCI) will build upon previous Wellcome Trust and Medical Research Council funding by drawing together 30 research teams into a cohesive centre. These groups will ultimately be co-located in a purpose-designed 8000m2 facility to be constructed on the Cambridge Biomedical Research Campus. The overall objective of this proposal is to define the potential of stem cell biology for human medicine. This relies on assembling a critical mass of talent in fundamental stem cell science alongside investigators focussed on translation to medical applications. The Cambridge Stem Cell Institute will be broad-based, well-resourced and intellectually invigorating. Cross-fertilisation between pluripotent and tissue stem cell biology will stimulate basic discoveries and increase capacity to address issues of human health and disease. Based on acquiring a deep understanding of stem cells allied with a clinical perspective, Institute scientists will pioneer innovative therapeutic approaches to unmet medical needs. Platform technologies supported by a Centre grant will enable SCI to recruit and retain the most talented investigators and empower them to make ground-breaking advances in understanding stem cells and their medical applications. Fundamental research will focus at the molecular level on mechanisms of self-renewal, commitment, differentiation and reprogramming. Functional studies will address the role of stem cells in development, repair, ageing, physiology and pathologies including cancer. Disease-specific induced pluripotent stem cells will be exploited to unravel mechanisms of cellular pathogenesis and define drug targets. Strategies to mobilise endogenous stem cells for regeneration will be evaluated in animal models and in the clinic as will approaches based on cell transplantation. The Institute will provide comprehensive training in embryonic and adult stem cell biology and will seek, and offer unique opportunities for, bioindustry interaction and collaboration.
Objectives
The objectives for SCI are:
(i) to uncover fundamental principles of stem cell identity, regulation and function;
(ii) to translate this knowledge into new tools for drug discovery and diagnostics;
(iii) to pioneer therapeutic approaches based on recruitment of endogenous stem cells and/or cell transplantation strategies.
Objectives
The objectives for SCI are:
(i) to uncover fundamental principles of stem cell identity, regulation and function;
(ii) to translate this knowledge into new tools for drug discovery and diagnostics;
(iii) to pioneer therapeutic approaches based on recruitment of endogenous stem cells and/or cell transplantation strategies.
Organisations
- University of Cambridge (Lead Research Organisation)
- University of Milan (Collaboration)
- ETH Zurich (Collaboration)
- LOUGHBOROUGH UNIVERSITY (Collaboration)
- The Hospital for Sick Children (SickKids) (Collaboration)
- CN Bio Innovations Ltd (Collaboration)
- Friedrich Miescher Institute for Biomedical Research (FMI) (Collaboration)
- Baylor College of Medicine (Collaboration)
- Bellvitge Biomedical Research Institute (Collaboration)
- Keio University (Collaboration)
- Microsoft Research (Collaboration)
- Norwegian University of Science and Technology (NTNU) (Collaboration)
- Dando, Weiss & Colucci Ltd (Collaboration)
- Chinese Academy of Medical Sciences (CAMS) (Collaboration)
- Cancer Research UK Cambridge Institute (Collaboration)
- University Libre Bruxelles (Université Libre de Bruxelles ULB) (Collaboration)
- University of Zurich (Collaboration)
- NsGene A/S (Collaboration)
- German Cancer Research Center (Collaboration)
- Johns Hopkins University (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- Icahn School of Medicine at Mount Sinai (Collaboration)
- Pasteur Institute, Paris (Collaboration)
- European Molecular Biology Laboratory (Collaboration)
- The Walter and Eliza Hall Institute of Medical Research (WEHI) (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- Central Institute for Experimental Animals (CIEA) (Collaboration)
- Francis Crick Institute (Collaboration)
- University of Copenhagen (Collaboration)
- British Council (Collaboration)
- Newcastle University (Collaboration)
- StemCells, Inc. (Collaboration)
- Erasmus MC (Collaboration)
- Stemcell Technologies (Collaboration)
- NeuroNova AB (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- UNIVERSITY OF EXETER (Collaboration)
- McGill University (Collaboration)
- Spanish National Centre for Cardiovascular Research (Collaboration)
- Gaslini Children's Hospital (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Academy of Sciences of the Czech Republic (Collaboration)
- Acerta (Collaboration)
- Medical University of Wurzburg (Collaboration)
- Galvani Bioelectronics Ltd (Collaboration)
- IRCCS Oasi Maria SS (Collaboration)
- Radboud University Nijmegen Medical Center (Collaboration)
- Ferring Pharmaceuticals (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- Medical College of Wisconsin (Collaboration)
- Domainex (Collaboration)
- Kymab (Collaboration)
- Yale University (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Autolus Limited (Collaboration)
- National Institutes of Health (NIH) (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- PLATOD (Collaboration)
- DefiniGEN (Collaboration)
- California Institute of Technology (Collaboration)
- University of Basel (Collaboration)
- National University of Ireland, Galway (Collaboration)
- University of Navarra Clinic (Collaboration)
- Penn State University (Collaboration)
- PhoreMost (Collaboration)
- QUEEN MARY UNIVERSITY OF LONDON (Collaboration)
- Boston University (Collaboration)
- Netherlands Cancer Institute (NKI) (Collaboration)
- University of Leipzig (Collaboration)
- University of Salento (Collaboration)
- RIKEN (Collaboration)
- Bit.Bio (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Mount Sinai Hospital (USA) (Collaboration)
- University of Bristol (Collaboration)
- Uniformed Services University of the Health Services (Collaboration)
- University of Buenos Aires (Collaboration)
- Babraham Institute (Collaboration)
- Korea Advanced Institute of Science and Technology (KAIST) (Collaboration)
- Sapio (Collaboration)
- National Institute for Health Research (Collaboration)
- Trinity College Dublin (Collaboration)
- University Hospital Zürich (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- AstraZeneca (United Kingdom) (Collaboration)
- University of Sussex (Collaboration)
- Tokyo Electron (Collaboration)
- Swiss Federal Institute of Technology in Lausanne (EPFL) (Collaboration)
- Lund University (Collaboration)
- University of California, Davis (Collaboration)
- University of Queensland (Collaboration)
- Cornell University (Collaboration)
- Tohoku University (Collaboration)
- University Medical Center Gronigen (Collaboration)
- CellCentric Ltd (Collaboration)
- Karolinska Institute (Collaboration)
- University Hospital of Basel (Collaboration)
- Cambridge Design Partnership (Collaboration)
- University of California, San Francisco (Collaboration)
- University of Kyoto (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- Centre for Genomic Regulation (CRG) (Collaboration)
- Kumamoto University (Collaboration)
- Helmholtz Association of German Research Centres (Collaboration)
- Numedicus Limited (Collaboration)
- École Normale Supérieure, Paris (Collaboration)
- Stem Cell Technologies (Collaboration)
- Center of Regenerative Medicine in Barcelona (Collaboration)
- EMBL European Bioinformatics Institute (EMBL - EBI) (Collaboration)
- Leiden University Medical Center (Collaboration)
- University of Sheffield (Collaboration)
- University of Bath (Collaboration)
- Alternative Energies and Atomic Energy Commission (CEA) (Collaboration)
- University of Hawaii (Collaboration)
- University Medical Center Utrecht (UMC) (Collaboration)
- Cell Guidance Systems Ltd (Collaboration)
- Hemoshear Therapeutics (Collaboration)
- Claudius Regaud Hospital (Collaboration)
- Agency for Science, Technology and Research (A*STAR) (Collaboration)
- Biogen (Collaboration)
- HARVARD UNIVERSITY (Collaboration)
- Royal Netherlands Academy of Arts and Sciences (Collaboration)
- University of Kumamoto (Collaboration)
- San Raffaele Hospital (Collaboration)
- National Institute of Health and Medical Research (INSERM) (Collaboration)
- Oxford Gene Technology (Collaboration)
- Tampere University of Technology (Collaboration)
- Hebrew University of Jerusalem (Collaboration)
- University of Paris - Descartes (Collaboration)
- Miltenyi Biotec GmBH (Collaboration)
- The University of Texas at San Antonio (Collaboration)
- University of Dundee (Collaboration)
- University Hospital Carl Gustav Carus Dresden (Collaboration)
- Cancer Research UK (Collaboration)
- Research Network Services (RNSL) Ltd Berlin (Collaboration)
- Chinese Academy of Sciences (Collaboration)
- Life and Brain GmbH (Collaboration)
- University of Vermont (Collaboration)
- Institute of Biomedical Imagery (I2BM) (Collaboration)
- Gustave-Roussy Institute (Collaboration)
- Justus Liebig University Giessen (Collaboration)
- Free University of Amsterdam (Collaboration)
- University of Toronto (Collaboration)
- University of Georgia (Collaboration)
- Austrian Academy of Sciences (Collaboration)
- UNIVERSITY OF BRITISH COLUMBIA (Collaboration)
- European Institute of Oncology (IEO) (Collaboration)
- ROYAL PAPWORTH HOSPITAL NHS FOUNDATION TRUST (Collaboration)
- University of Oslo (Collaboration)
- Cell Therapy Catapult (Collaboration)
- University at Buffalo (Collaboration)
- UK Regenerative Medicine Platform (Collaboration)
- Novo Nordisk (Collaboration)
- Memorial Sloan Kettering Cancer Center (Collaboration)
- University of Kentucky (Collaboration)
- Institute of Genetics and Molecular and Cellular Biology (IGBMC) (Collaboration)
- UK Clinical Research Collaboration (Collaboration)
- Max Planck Society (Collaboration)
- Albert Einstein College of Medicine (Collaboration)
- Pfizer Ltd (Collaboration)
- Cardiff University (Collaboration)
- Technical University of Dresden (Collaboration)
- University Health Network (UHN) (Collaboration)
- UNSW Sydney (Collaboration)
- Swiss Institute of Bioinformatics (SIB) (Collaboration)
- Roche Pharmaceuticals (Collaboration)
- University of Helsinki (Collaboration)
- University of Valencia (Collaboration)
- JDRF Center for Beta Cell Therapy in Diabetes (Collaboration)
- Sheba Medical Centre (Collaboration)
- University of Manchester (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- University of Groningen (Collaboration)
- Washington University in St. Louis (Collaboration)
- University of Veterinary Medicine Vienna (Collaboration)
- Hospital Son Espases (Collaboration)
- University of Turku (Collaboration)
- Technical University of Denmark (Collaboration)
- Weizmann Institute of Science (Collaboration)
- Ministry of the Environment (Collaboration)
- Royal Institute of Technology (Collaboration)
- University of Leuven (Collaboration)
- University of Bonn (Collaboration)
- University of Washington (Collaboration)
People |
ORCID iD |
Publications
Santos DP
(2016)
Comprehensive Protocols for CRISPR/Cas9-based Gene Editing in Human Pluripotent Stem Cells.
in Current protocols in stem cell biology
Rui L
(2016)
Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.
in Proceedings of the National Academy of Sciences of the United States of America
Daley GQ
(2016)
Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines.
in Stem cell reports
Picaud S
(2016)
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia
in Science Advances
Dee CT
(2016)
CD4-Transgenic Zebrafish Reveal Tissue-Resident Th2- and Regulatory T Cell-like Populations and Diverse Mononuclear Phagocytes.
in Journal of immunology (Baltimore, Md. : 1950)
Crawford A
(2016)
Pre-Existing Mature Oligodendrocytes Do Not Contribute to Remyelination following Toxin-Induced Spinal Cord Demyelination
in The American Journal of Pathology
Collinson A
(2016)
Deletion of the Polycomb-Group Protein EZH2 Leads to Compromised Self-Renewal and Differentiation Defects in Human Embryonic Stem Cells
in Cell Reports
Rouhani FJ
(2016)
Mutational History of a Human Cell Lineage from Somatic to Induced Pluripotent Stem Cells.
in PLoS genetics
Sciacovelli M
(2016)
Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.
in Nature
Carbognin E
(2016)
Stat3 promotes mitochondrial transcription and oxidative respiration during maintenance and induction of naive pluripotency.
in The EMBO journal
| Title | Stem Cell Revolutions |
| Description | Austin Smith provided the voice over for the Stem Cell Revolutions film. Featuring beautiful hand-drawn animations and interviews with leading stem cell scientists, Stem Cell Revolutions charts the history and scientific evolution of stem cell research - from the earliest experiments that first revealed stem cells in the body, to leading current scientific and clinical developments |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2013 |
| Impact | Increased understanding of Stem Cell Biology on an international scale |
| URL | http://www.stemcellrevolutions.com/watch |
| Description | Advisory board member for: Izmir Biomedicine and Genome Center, Dokuz Eylul University, Turkey |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | AstraZeneca, Stem Cell & Primary Cell Scientific Advisory Board, Sweden |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Briefing of Policy Advisor |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Briefing of Wellcome Trust Policy Advisor |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Briefing of Wellcome Trust Policy Advisor - Dr Alexis Gilbert |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | CDB |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Cell Fate and Cancer Programme, Centre for Genomic Regulation, Barcelona, Spain |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Cell Therapy Catapult Academic Advisory Board, London, UK |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Cell and Gene Therapy Catapult Scientific Advisory Board |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | CiRA Symposium, Kyoto |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | CiRA Symposium, Kyoto |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Global COE programme, Kyoto |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Guideline Title | Guideline for the treatment of chronic lymphocytic leukaemia |
| Description | Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.15460 |
| Description | Health Education England's Genomic Education Programme's Competency Framework Review |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Impact | Health Education England's Genomic Education Programme's Competency Framework Review for obtaining informed consent for genomic testin. |
| Description | ISSCR - keynote speaker |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | ISSCR Advisory Board |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | ISSCR Board of Directors Meeting |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | International Scientific Advisory Board Annual Meeting 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | MEP Briefing |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | MEP Forum - Brussels |
| Geographic Reach | Europe |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Pontifical Academy of Sciences |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Riken Advisory Committee |
| Geographic Reach | Asia |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Riken Advisory Council |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Royal College of Surgeons (Ludovic Vallier) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.youtube.com/watch?v=wnYyJxXhkLE&t=13507s |
| Description | UKSCB Advisory Board |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Wellcome Trust Sanger Institute Cellular Genetics Programme |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | (ChRONAM-H) - Chromatin Regulation Of Normal And Malignant Haematopoiesis |
| Amount | € 212,934 (EUR) |
| Funding ID | 886474 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 10/2020 |
| End | 09/2022 |
| Description | (HARMONY PLUS) - HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY - PLUS |
| Amount | € 11,882,669 (EUR) |
| Funding ID | 945406 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 10/2020 |
| End | 09/2023 |
| Description | (NSC-Reconstruct) - Novel Strategies for Cell-based Neural Reconstruction |
| Amount | € 8,169,231 (EUR) |
| Funding ID | 874758 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2020 |
| End | 12/2023 |
| Description | (PATRES-MDS) - Pathogenesis and treatment of splicing factor mutant myelodysplastic syndromes |
| Amount | € 1,999,771 (EUR) |
| Funding ID | 819956 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 05/2019 |
| End | 04/2024 |
| Description | 3RD SCIENTIFIC WORKSHOP |
| Amount | £5,000 (CLF) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 06/2019 |
| Description | A Reference Cell Atlas of Human Liver Diversity Over a Lifespan |
| Amount | £150,000 (GBP) |
| Organisation | Chan Zuckerberg Initiative |
| Sector | Private |
| Country | United States |
| Start | 09/2019 |
| End | 08/2021 |
| Description | Addenbrookes Charitable Trust award of Consumables for Dr. K.Kurian to work within Biochemistry: Stem Cell Institute |
| Amount | £10,000 (GBP) |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Advanced Clinician Scientist Fellowship (Simon Buczacki) |
| Amount | £1,500,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2023 |
| Description | Advanced grant: New-Chol: Development of new therapies against Cholangiopathies (Ludovic Vallier) |
| Amount | £2,200,000 (GBP) |
| Funding ID | 741707 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 12/2017 |
| End | 11/2022 |
| Description | Age related changes in alternative splicing in oligodendrocyte progenitor cells (Robin Franklin) |
| Amount | £591,058 (GBP) |
| Organisation | Biogen |
| Sector | Private |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 06/2021 |
| Description | Authentication of primate pluripotent stem cells for chimaera formation |
| Amount | £530,915 (GBP) |
| Funding ID | MR/S020845/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 02/2022 |
| Description | BB/H012737/1 Gene Targetting by homologous recombination in the Rat |
| Amount | £612,215 (GBP) |
| Funding ID | BB/H012737/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2011 |
| End | 05/2015 |
| Description | BBSRC Stem Cell Potency |
| Amount | £841,267 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2006 |
| End | 02/2008 |
| Description | BIG regulates the circadian clock and development (equipment) (Robin Franklin) |
| Amount | £251,744 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 10/2023 |
| Description | Beit Memorial Fellowship for Medical Research |
| Amount | £126,043 (GBP) |
| Organisation | Wellcome Trust |
| Department | Wellcome-Beit Prize Fellowships |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2007 |
| End | 09/2010 |
| Description | BetaCellTherapy: Beta Cell Therapy in Diabetes |
| Amount | £823,424 (GBP) |
| Funding ID | 241883 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2010 |
| End | 12/2014 |
| Description | Biogenesis and bioengineering of human platelets |
| Amount | £593,451 (GBP) |
| Funding ID | 219472/A/19/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 02/2025 |
| Description | Bioinformatic analyses of chromatin remodelling during cell fate transitions in embryonic stem cells (Brian Hendrich) |
| Amount | £21,982 (GBP) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 09/2018 |
| Description | Biotechnology for investigating cell fate choice |
| Amount | £1,660,723 (GBP) |
| Funding ID | 772798 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 04/2018 |
| End | 03/2023 |
| Description | Bronchiolar and Alveolar Organoids (Joo-Hyeon Lee) |
| Amount | £153,327 (GBP) |
| Organisation | AstraZeneca |
| Department | Astra Zeneca |
| Sector | Private |
| Country | United States |
| Start | 12/2017 |
| End | 12/2019 |
| Description | CALR mutations and human myeloproliferative neoplasms. |
| Amount | £2,000,004 (GBP) |
| Funding ID | 104710/Z/14/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2014 |
| End | 10/2019 |
| Description | CHARACTERISATION OF ALTERED EPIGENETIC CELL STATES FOLLOWING LOSS OF CREBBP FUNCTION AND THEIR ROLE IN THE INDUCTION AND TREATMENT OF ALL |
| Amount | £1,219,270 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 05/2024 |
| Description | CHARACTERIZATION OF ZAP70-MEDIATED SIGNALLING PATHWAYS IN DI (Ingo Ringshausen) |
| Amount | £218,332 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | CHINA - UK STEM CELL SYMPOSIUM |
| Amount | £18,000 (GBP) |
| Organisation | British Council |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2019 |
| Description | CROSS TALK BETWEEN REPRESSIVE HISTONE MODIFICATIONS AND DNA METHYLATION IN THE PATHOGENESIS AND EVOLUTION OF MYELOID MALIGNANCIES |
| Amount | £240,282 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2021 |
| Description | Cambridge Biomedical Research Centre - funding for Cancer Molecular Diagnostic Laboratory |
| Amount | £1,175,000 (GBP) |
| Organisation | Cambridge University Hospitals NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2022 |
| Description | Cambridge Biomedical research Centre - funding for Cambridge Blood and Stem Cell Biobank |
| Amount | £1,061,140 (GBP) |
| Organisation | Cambridge University Hospitals NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2022 |
| Description | Cambridge Cancer Centre Studentship |
| Amount | £195,918 (GBP) |
| Organisation | Cambridge Cancer Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2020 |
| Description | Cambridge Doctoral Training Partnership |
| Amount | £96,736 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2021 |
| Description | Capturing formative pluripotency (Austin Smith) |
| Amount | £662,127 (GBP) |
| Funding ID | BB/P009867/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2020 |
| Description | Catherine Dubrowska consumables (Lee lab) |
| Amount | £39,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2021 |
| Description | Centre for Stem Cell Biology & Regenerative Medicine |
| Amount | £795,134 (GBP) |
| Funding ID | G0800784 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2009 |
| End | 12/2011 |
| Description | Characterisation of new human ES cell derived in novel |
| Amount | £55,624 (GBP) |
| Funding ID | 4-2005-821 |
| Organisation | Juvenile Diabetes Research Foundation (JDRF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2007 |
| End | 12/2007 |
| Description | Collaborative bursary MiRNA expression in brain cancer stem cells |
| Amount | £6,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Connecting Cambridge (Chrysa Kapeni) |
| Amount | £39,197 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 10/2018 |
| Description | Core Support for Wellcome Trust Centre for Stem Cell Research |
| Amount | £6,956,531 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2007 |
| End | 12/2011 |
| Description | Cystic Fibrosis Innovation Hub Award (Ludovic Vallier) |
| Amount | £145,000 (GBP) |
| Organisation | Cystic Fibrosis Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2023 |
| Description | DECIPHERING LEUKAEMOGENIC MECHANISMS BY INTEGRATED SYSTEMS-SCALE ANALYSIS |
| Amount | £299,538 (GBP) |
| Organisation | Bloodwise |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 02/2022 |
| Description | DECIPHERING THE ROLE OF C/EBPX IN THE EVOLUTION OF HAEMATOLOGY (Bertie Gottgens) |
| Amount | £29,172 (GBP) |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 02/2019 |
| Description | DEVELOPMENT OF A LYMPHOMA-SPECIFIC MUTANT OPEN READING FRAME (MORF) LIBRARY |
| Amount | £34,400 (GBP) |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2019 |
| End | 06/2020 |
| Description | DEVELOPMENT OF NEW METHOD OF DIFFERENTIATION FOR HEPATOCYTES |
| Amount | £113,477 (GBP) |
| Organisation | DefiniGEN |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2021 |
| Description | Deciphering and overcoming epigenetic erosion at imprinted loci in mouse and human naïve pluripotent stem cells |
| Amount | £417,766 (GBP) |
| Funding ID | BB/R018588/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 06/2021 |
| Description | Deciphering myeloid landscape of non-small cell lung cancer |
| Amount | £1,022,207 (GBP) |
| Organisation | The Wellcome Trust Sanger Institute |
| Department | Open Targets |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 03/2022 |
| Description | Decoding the network logic for decoding pluripotency (Austin Smith) |
| Amount | £111,786 (GBP) |
| Funding ID | BB/P021573/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2019 |
| Description | Defining the Haematopoietic System through Integrated Multi-Scale Analysis (Bertie Gottgens) |
| Amount | £2,028,031 (GBP) |
| Funding ID | 206328 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2023 |
| Description | Defining the molecular consequences of mutations that disrupt early heart development (Bertie Gottgens) |
| Amount | £13,000 (GBP) |
| Organisation | Wiener-Anspach Foundation |
| Sector | Charity/Non Profit |
| Country | Belgium |
| Start | 10/2018 |
| End | 12/2020 |
| Description | Defining the prerequisites of naïve pluripotent human embryo cells for self-renewal in culture (Jenny Nichols) |
| Amount | £683,801 (GBP) |
| Funding ID | MR/P010423/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | Delimiting the stem cell phase boundary via time normalisation (Austin Smith) |
| Amount | £224,408 (GBP) |
| Organisation | The Leverhulme Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 01/2019 |
| Description | Developing new models for the functional investigation of Lymphoma |
| Amount | £104,000 (GBP) |
| Organisation | Gilead Sciences, Inc. |
| Department | Gilead |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2019 |
| Description | Druggable epigenetic control by modulation of a transcriptional master-regulator: switching neuroblastoma from a proliferative to a differentiation programme (Anna Philpott) |
| Amount | £1,600,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2023 |
| Description | ERC Advanced Grant: Myelin at the crossroads of Development and Disease (David Rowitch) |
| Amount | £1,785,714 (GBP) |
| Funding ID | 789054 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 10/2018 |
| End | 09/2023 |
| Description | ESTOOLS: Platforms for Biomedical Discovery with Human ES cells |
| Amount | £373,970 (GBP) |
| Funding ID | 18739 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 08/2006 |
| End | 07/2010 |
| Description | EURATRANS European large-scale functional genomics in the rat for translational research (10.5m euros across 19 participants) |
| Amount | £517,672 (GBP) |
| Funding ID | 241504 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 04/2010 |
| End | 09/2014 |
| Description | EUROSTEMCELL: European Consortium for Stem Cell Research (0.8m euros across 11 participants) |
| Amount | £38,175 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 09/2006 |
| End | 01/2008 |
| Description | EUROSTEMCELL: European Consortium for Stem Cell Research (0.8m euros across 11 participants) |
| Amount | £6,457 (GBP) |
| Funding ID | 241878 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 03/2010 |
| End | 02/2015 |
| Description | EUROSYSTEM European consortium for systematic stem Cell Biology (12m euros across 24 participants) |
| Amount | £1,184,402 (GBP) |
| Funding ID | 200720 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 03/2008 |
| End | 08/2012 |
| Description | Early Detection Markers for Gastroesophageal Cancer; a Proteomic Perspective of Epithelial-Stromal Crosstalk. |
| Amount | £248,437 (GBP) |
| Funding ID | 19-0192 |
| Organisation | Worldwide Cancer Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 04/2021 |
| Description | Elucidation of cellular and molecular mechanisms of lymphoma induction and evolution to identify therapeutic targets |
| Amount | £755,910 (GBP) |
| Funding ID | MR/R009708/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2021 |
| Description | Embryonic Stem Cells, Neural stem cells and Neurons |
| Amount | £102,527 (GBP) |
| Organisation | Fidelity Biosciences |
| Sector | Private |
| Country | United States |
| Start | 05/2007 |
| End | 05/2009 |
| Description | Engineered Cell Environment (Andrew McCaskie) |
| Amount | £416,196 (GBP) |
| Organisation | UK Regenerative Medicine Platform |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2023 |
| Description | Enhancer subversion and its role in the generation and maintenance of Acute Myeloid Leukaemia |
| Amount | £1,728,779 (GBP) |
| Funding ID | 25508 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2023 |
| Description | Fellowship for abroad - Dorian Forte |
| Amount | £113,822 (GBP) |
| Organisation | AIRC Foundation for Cancer Research in Italy |
| Sector | Public |
| Country | Italy |
| Start | 02/2018 |
| End | 01/2020 |
| Description | Generating platelets in vitro for the clinic: optimisation and added clinical efficacy |
| Amount | £474,809 (GBP) |
| Funding ID | MR/V005413/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 09/2023 |
| Description | Generation of human iPSC- derived motor neurons and microglia to model ALS pathophysiology in a dish (Stefano Pluchino) |
| Amount | £7,800 (GBP) |
| Organisation | University of Montreal |
| Department | Montreal Neurological Institute |
| Sector | Hospitals |
| Country | Canada |
| Start | 01/2017 |
| End | 12/2017 |
| Description | Genetic screen to identify new target for NAFLD/NASH |
| Amount | £250,000 (GBP) |
| Organisation | University of Cambridge |
| Department | Milner Therapeutics Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 08/2021 |
| Description | HARMONY - Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in hematology |
| Amount | £130,435 (GBP) |
| Funding ID | 116026 |
| Organisation | European Federation of Pharmaceutical Industries and Associations (EFPIA) |
| Sector | Private |
| Country | Belgium |
| Start | 01/2017 |
| End | 12/2021 |
| Description | HUMAN DEVELOPMENTAL BIOLOGY INITIATIVE |
| Amount | £1,770,671 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2024 |
| Description | Heterogeneity of the human epicardium: molecular determinants and functional consequences (Sanjay Sinha) |
| Amount | £185,375 (GBP) |
| Funding ID | PG/17/24/32886 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2019 |
| Description | Horizon2020 FTE grant |
| Amount | £2,641,920 (GBP) |
| Organisation | European Union |
| Sector | Public |
| Country | European Union (EU) |
| Start | 11/2017 |
| End | 12/2021 |
| Description | How does ageing affect remyelination potential? |
| Amount | £257,498 (GBP) |
| Organisation | Dr. Miriam and Sheldon G. Adelson Medical Research Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 10/2017 |
| End | 09/2018 |
| Description | Human Cell Atlas (Bertie Gottgens) |
| Amount | £390,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2018 |
| End | 04/2021 |
| Description | IDENTIFICATION AND FUNCTIONAL VALIDATION OF GENES INVOLVED IN NON-ALCOHOLIC FATTY LIVER DISEASE |
| Amount | £248,669 (GBP) |
| Organisation | The Wellcome Trust Sanger Institute |
| Department | Open Targets |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 02/2022 |
| Description | IDENTIFICATION AND VALIDATION OF TRACTABLE TARGETS FOR REJUVENATION |
| Amount | £516,000 (GBP) |
| Organisation | Dementia Discovery Fund |
| Sector | Private |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 08/2022 |
| Description | IMAGING REMEYLINATION IN THE CENTRAL NERVOUS SYSTEM |
| Amount | £282,280 (GBP) |
| Organisation | Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 01/2022 |
| Description | Identification and characterisation of metabolic pathways as determinants of drug responses in acute myloid leukaemia (AML) - Paolo Gallipoli |
| Amount | £103,703 (GBP) |
| Organisation | American Society of Haematology (ASH) |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 08/2018 |
| End | 03/2020 |
| Description | Identification and functional validation of genes involved in non-alcoholic steatohepatitis liver disease |
| Amount | £650,000 (GBP) |
| Organisation | The Wellcome Trust Sanger Institute |
| Department | Open Targets |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 10/2020 |
| Description | Identification of disease modifying treatments for PD, using patient-derived induced neurons (Roger Barker) |
| Amount | £127,246 (GBP) |
| Organisation | Cure Parkinson's Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2019 |
| Description | Identification of pathogenic autoantibodies in stiff person syndrome (Thora Karadottir) |
| Amount | £23,256 (GBP) |
| Organisation | National Organization for Rare Disorders (NORD) |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 10/2018 |
| End | 10/2020 |
| Description | Impact of Cell & Gene Therapy onthe function and molecular regulation of haematopoietic stem cells (Elisa Laurenti) |
| Amount | £136,627 (GBP) |
| Funding ID | 1942750 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2021 |
| Description | Improving haematopoietic reconstitution in blood stem cell transplantation procedures through the regulation of stem cells and their niches |
| Amount | £634,921 (GBP) |
| Funding ID | MR/V005421/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 09/2023 |
| Description | Interdisciplinary prize: Generation and transplantation of a bioengineered human bile duct (Ludovic Vallier) |
| Amount | £250,000 (GBP) |
| Funding ID | M787 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2020 |
| Description | Isaac Newton Trust |
| Amount | £37,297 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2019 |
| Description | Isaac Newton Trust |
| Amount | £29,346 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 05/2019 |
| Description | Japanese Partnership |
| Amount | £56,594 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2010 |
| End | 06/2014 |
| Description | Junior Research Grant |
| Amount | € 100,000 (EUR) |
| Funding ID | RG65 |
| Organisation | European Hematology Association (EHA) |
| Sector | Charity/Non Profit |
| Country | Netherlands |
| Start | 10/2020 |
| End | 09/2022 |
| Description | Kelly Evans iCase Studentship with AstraZeneca (Lee Lab) |
| Amount | £130,212 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2021 |
| Description | LEVERAGING HYPOXIA-INDUCED EPIGENETIC HETEROGENEITY IN LUNG CANCER |
| Amount | £37,500 (GBP) |
| Organisation | Hope Funds for Cancer research |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 07/2019 |
| End | 06/2021 |
| Description | MAHA ALFAIDI - PHD FEES AND CONSUMABLES |
| Amount | £34,595 (GBP) |
| Organisation | Saudi Arabian Cultural Bureau |
| Sector | Public |
| Country | Canada |
| Start | 04/2019 |
| End | 05/2020 |
| Description | MRC Confidence in Concept - University of Cambridge: Improving gene therapy protocol efficacy by modulating haematopoietic stem cell exit from quiescence (Elisa Laurenti) |
| Amount | £64,094 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 10/2018 |
| Description | MRC Stem Cell Career Development Fellowship |
| Amount | £279,872 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2008 |
| End | 07/2011 |
| Description | Mathematical Genomics and Medicine Programme PhD studentship |
| Amount | £40,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2020 |
| Description | Mathematical clonal analysis of cancer initiating cells in homeostasis and injury-repair using modified Rosa-confetti alleles in diverse tissues |
| Amount | £386,713 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 01/2020 |
| Description | Mechanisms of adhesion-dependent haematopoietic transdetermination |
| Amount | £575,124 (GBP) |
| Funding ID | MR/T028343/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2020 |
| End | 07/2023 |
| Description | Mechanisms of lineage restriction in development and reprogramming. |
| Amount | £1,998,310 (GBP) |
| Funding ID | 212253/Z/18/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 09/2024 |
| Description | Mesenchymal contribution to early oesophagael cancer |
| Amount | £449,996 (GBP) |
| Funding ID | MR/P019013/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 04/2020 |
| Description | Microenvironmental metabolic regulation in myeloid malignancies (Simon Mendez-Ferrer) |
| Amount | £148,761 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2022 |
| Description | NeuroStemcell Project - European consortium for stem Cell therapy |
| Amount | £652,985 (GBP) |
| Funding ID | 222943 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 12/2008 |
| End | 05/2013 |
| Description | Neuronal Regulation of CNS Myelin Plasticity (Thora Karadottir) |
| Amount | £1,769,672 (GBP) |
| Funding ID | 771411 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 07/2018 |
| End | 05/2023 |
| Description | New therapeutic strategies for Marfan and other genetically-triggered aortic aneurysm syndromes (Sanjay Sinha) |
| Amount | £1,281,390 (GBP) |
| Funding ID | RG/17/5/32936 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2022 |
| Description | Novel approach to model Non-Alcoholic Fatty Liver Disease using human Pluripotent Stem Cells. |
| Amount | £115,646 (GBP) |
| Funding ID | NC/R001987/1 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 05/2020 |
| Description | Novel organoid models for chronic lung disease |
| Amount | £25,000 (GBP) |
| Organisation | British Lung Foundation (BLF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 03/2019 |
| Description | OESOPHAGEAL CELL PLASTICITY IN RESPONSE TO INJURY AND EARLY Tumorigenesis |
| Amount | £173,004 (GBP) |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 06/2019 |
| End | 05/2021 |
| Description | Ole Wiskow Studentship |
| Amount | £22,500 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 01/2007 |
| End | 12/2009 |
| Description | OncoLive | Optogenetic control and measurement of oncogenic mutations and signalling in organoid cultures for the biophysical modelling of early oncog |
| Amount | £245,019 (GBP) |
| Funding ID | NS/A000077/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 07/2022 |
| Description | Personalised cell-based and iron chelator therapies for hypomyelinating leukodystrophy (David Rowitch) |
| Amount | £84,447 (GBP) |
| Funding ID | 2431 |
| Organisation | Action Medical Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 11/2018 |
| Description | PhD Programme for Clinicians |
| Amount | £49,500 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 10/2020 |
| Description | PhD Studentship |
| Amount | £77,511 (GBP) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 09/2019 |
| End | 08/2023 |
| Description | PhD Studentship |
| Amount | £49,500 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2019 |
| End | 12/2022 |
| Description | PhD Studentship |
| Amount | £87,552 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 03/2023 |
| Description | PhD Studentship |
| Amount | £70,038 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 08/2022 |
| Description | PhD Studentship |
| Amount | £92,000 (GBP) |
| Organisation | National Institute for Health Research (NIHR) |
| Department | Oxford-Cambridge Scholars Program |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 08/2023 |
| Description | Plasticity of the Pluripotency Network |
| Amount | € 2,499,970 (EUR) |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 01/2020 |
| End | 12/2024 |
| Description | Platform to phenotype liver metabolic disorders |
| Amount | £50,000 (GBP) |
| Funding ID | NC/T2T0419 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 04/2020 |
| Description | Plurimes - Pluripotent Stem Cell Resources for Mesodermal Medicine |
| Amount | £1,511,268 (GBP) |
| Funding ID | 602423 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 02/2014 |
| End | 01/2018 |
| Description | Positive selection CRISPR screening in primary human B cells to elucidate the pathogenesis of DLBCL (Daniel Hodson) |
| Amount | £208,900 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2020 |
| Description | Precision Transgenesis in Rats via Embryonic Stem Cells |
| Amount | £52,827 (GBP) |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | 08/2006 |
| End | 01/2009 |
| Description | Programme Grant |
| Amount | £300,000 (GBP) |
| Organisation | Bloodwise |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 05/2020 |
| Description | Project Grant - An investigation of the pre-clinical evolution of TET2-mutant myeloid neoplasms (George Vassiliou) |
| Amount | £227,397 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2021 |
| Description | Provision for public engagement - Stem Cell Institute Public Engagement Officer |
| Amount | £171,011 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 06/2017 |
| Description | Re-defining the paradigm of X-chromosome inactivation |
| Amount | £416,235 (GBP) |
| Funding ID | MR/R017735/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 06/2021 |
| Description | Regulation and function of the pluripotency determinant Nanaog |
| Amount | £844,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2006 |
| End | 10/2010 |
| Description | Regulation of Self Renewal, Commitment and Differentiation in Brain Cancer Cells |
| Amount | £177,218 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2008 |
| End | 05/2011 |
| Description | Repurposing AMPAkines for enhancing myelin regeneration in Multiple Sclerosis |
| Amount | £130,000 (GBP) |
| Funding ID | 204488/Z/16/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 07/2018 |
| Description | Repurposing glutamate modulators for enhancing myelin regene |
| Amount | £70,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 10/2017 |
| Description | Resolving white matter disfunction in Alzheimer's disease with patient specific cell |
| Amount | £38,373 (GBP) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 07/2018 |
| Description | Royal Society Research Professorship |
| Amount | £791,000 (GBP) |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2023 |
| Description | Senior Cancer Research Fellowship (George Vassiliou) |
| Amount | £1,900,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 07/2023 |
| Description | Senior Clinical Fellowship: Human ESC-derived epicardium to promote cardiac regeneration and remusculation |
| Amount | £927,088 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 07/2023 |
| Description | Single cell isolation from heterogeneous normal and malignant cell populations |
| Amount | £50,000 (GBP) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 06/2018 |
| Description | Statistical physics of cell fate choice |
| Amount | £40,000 (GBP) |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 11/2019 |
| Description | Steering Embryonic Stem Cells towards Pancreatic |
| Amount | £43,902 (GBP) |
| Organisation | Juvenile Diabetes Research Foundation (JDRF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2007 |
| End | 04/2010 |
| Description | Stem Cell Initiative (Core Grant) |
| Amount | £1,143,873 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2006 |
| End | 12/2008 |
| Description | Stemstroke: Towards a Stem Cell Therapy for Stroke |
| Amount | £294,553 (GBP) |
| Funding ID | 37526 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2007 |
| End | 12/2009 |
| Description | Studentship Ms Amanda Anderson Rolf |
| Amount | £97,054 (GBP) |
| Funding ID | RG70550 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2013 |
| End | 09/2017 |
| Description | Summer Studentship for Magdelena Stasiulewicz |
| Amount | £2,500 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2010 |
| End | 08/2010 |
| Description | Supercharging platelets to prevent blood loss after trauma and regenerate hearts after heart attack |
| Amount | £60,000 (GBP) |
| Funding ID | M724 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 10/2020 |
| Description | SyBoSS Project - Systems Biology of Stem Cells and Reprogramming |
| Amount | £374,310 (GBP) |
| Funding ID | 242129 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 06/2010 |
| End | 05/2015 |
| Description | Synergistic Interaction Between the Master Regulator ASCL1 and Wnt Signaling Drives Neuroblastoma (Anna Philpott) |
| Amount | £58,920 (GBP) |
| Organisation | The Neuroblastoma Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 06/2018 |
| Description | THE TRANSCRIPTIONAL PROGRAMS OF MYELOPROLIFERATIVE NEOPLASMS |
| Amount | £800,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 01/2022 |
| Description | THE TRANSCRIPTIONAL PROGRAMS OF MYELOPROLIFERATIVE NEOPLASMS |
| Amount | £689,196 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 01/2022 |
| Description | The Discovery of future Neuro-therapeutic Molecules (NEUROscreen) |
| Amount | £195,139 (GBP) |
| Funding ID | 37766 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 08/2007 |
| End | 07/2010 |
| Description | The Pluripotent Stem Cells and Engineered Cell (PSEC) hub (Cedric Ghevaert) |
| Amount | £280,337 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 05/2023 |
| Description | The Road from Pluripotency to Lineage |
| Amount | £1,736,222 (GBP) |
| Funding ID | 091484 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2010 |
| End | 10/2015 |
| Description | The Stat3 pathway in Stem Cell Self renewal and the germline |
| Amount | £1,211,904 (GBP) |
| Funding ID | BB/G015678/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2009 |
| End | 05/2013 |
| Description | The engineered cell environment (Robin Franklin) |
| Amount | £460,906 (GBP) |
| Funding ID | MR/R015635/1 |
| Organisation | UK Regenerative Medicine Platform |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2021 |
| Description | The impact f genomic and microenvironmental factors on phenotype myeloproliferative neoplasms |
| Amount | £33,166 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 01/2018 |
| Description | Towards stem cell based therapies of leukemia: understanding the functional effects of preleukemic mutations on human haematopoietic stem cells (Elisa Laurenti) |
| Amount | £381,174 (GBP) |
| Organisation | British Council |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2021 |
| Description | Transcriptional control of cell fate decisions by chromatin remodelling proteins |
| Amount | £758,156 (GBP) |
| Funding ID | MR/R009759/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2020 |
| Description | Transcriptional programmes of myeloproliferative neoplasms |
| Amount | £1,489,605 (GBP) |
| Funding ID | A12765 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 01/2022 |
| Description | Transplantation protocols to assess the ability of ES cell derived endodermal populations to differentiate towards pancreatic lineages |
| Amount | £26,596 (GBP) |
| Organisation | Juvenile Diabetes Research Foundation (JDRF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | UKRMP2 (PSEC) (Roger Barker) |
| Amount | £3,539,266 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 05/2023 |
| Description | UNDERSTANDING THE GENETIC ALTERATIONS THAT CAUSE LYMPHOMA |
| Amount | £62,543 (GBP) |
| Organisation | The Evelyn Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 09/2022 |
| Description | Understanding The Contribution Of Notch1 Mutations To Treatment Response And Cellular Transformation In Cll |
| Amount | £220,287 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 04/2022 |
| Description | Understanding how the nurd complex assembles and functions in mouse embryonic stem cells |
| Amount | £20,160 (GBP) |
| Funding ID | MR/P019471/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 04/2022 |
| Description | Understanding mammalian interphase genome structure in mouse |
| Amount | £254,618 (GBP) |
| Funding ID | 206291/Z/17/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 04/2022 |
| Description | Understanding the physical biology of adult blood stem cells |
| Amount | £1,304,348 (GBP) |
| Funding ID | 715371 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 05/2017 |
| End | 04/2022 |
| Description | WT Research Training Fellowship: Lay Ping Ong. Does Epicardium promote Cardiomyocyte Maturation and Cardiac Regeneration? (Sanjay Sinha) |
| Amount | £270,886 (GBP) |
| Funding ID | 203568/Z/16/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | Wellcome 4-Year (1+3) PhD Programme in Stem Cell Biology & Medicine |
| Amount | £660,528 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2022 |
| Description | Wellcome Trust 4-Year Studentship - 5 year funding |
| Amount | £2,512,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| Title | 'Cell Map' of early mammalian development |
| Description | technology to profile over 20,000 individual cells from the developing embryo to produce the first 'cell map' describing all of the major cell types present in early embryo development. The researchers used the map to identify an important new pathway involved in blood cell development and say the map could open up new avenues for medicine and drug development. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | The 'cell map' data also offers new drug development opportunities which could lead to future impacts.The identification of new pathways driving normal blood cell development has the potential to improve our ability to generate blood cells for these patients in the laboratory". This is a comprehensive and deep characterisation of cell types present in the mouse embryo at this critical stage of development, creating a rich resource for the community. The study illustrates the power of single cell based techniques to understand the development of organs such as the heart and brain. It could also help researchers to improve methods for creating mature, specialised cells from stem cells. |
| URL | https://www.nature.com/articles/s41556-017-0013-z |
| Title | Computer Model to simulate blood production from stem cells |
| Description | CSCI and Microsoft Research developed the first computer model to simulate the growth of blood cells from stem cells. This programme will help in the development of new treatments for blood cancer. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | The new computer model enables researchers to carry out simulated experiments in seconds that would normally take many weeks to perform in the lab. The model will dramatically speed up research into blood development and the genetic mutations that cause leukaemia. |
| URL | http://www.nature.com/articles/nbt.3154 |
| Description | Academic collaboration - Brian Huntly |
| Organisation | Queen Mary University of London |
| Department | Barts Cancer Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - academic collaboration |
| Collaborator Contribution | Collaboration with Paolo Gallipoli - academic collaboration |
| Impact | None yet |
| Start Year | 2019 |
| Description | Ana Cvejic - EBI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ana Cvejic - Collaborative project |
| Collaborator Contribution | Collaborative research with Moritz Gerstung of the EMBL European Bioinformatics Institute. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Ana Cvejic - ISB-SIB |
| Organisation | Swiss Institute of Bioinformatics (SIB) |
| Country | Switzerland |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Ana Cvejic; Co-author on paper. |
| Collaborator Contribution | Collaboration with David Gfeller; Co-author on paper. |
| Impact | Co-author on paper. |
| Start Year | 2014 |
| Description | Ana Cvejic - Sanger |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Ana Cvejic; Co-author on paper. |
| Collaborator Contribution | Collaboration with Sarah Teichmann; Co-author on paper. |
| Impact | Co-author on paper. |
| Start Year | 2015 |
| Description | Ana Cvejic - Sanger (Macaulay) |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Ana Cvejic; Co-author on paper. |
| Collaborator Contribution | Collaboration with Ian Macaulay; Co-author on paper. |
| Impact | Co-author on paper. |
| Start Year | 2015 |
| Description | Ana Cvejic - University of Cambridge (Haematology) |
| Organisation | University of Cambridge |
| Department | Cambridge Stem Cell Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ana Cvejic; Co-author on paper. |
| Collaborator Contribution | Collaboration with Willem Ouwehand; Co-author on paper. |
| Impact | Co-author on paper. |
| Start Year | 2012 |
| Description | Ana Cvejic - University of Manchester |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ana Cvejic; Co-author on paper. |
| Collaborator Contribution | Collaboration with Adam Hurlstone; Co-author on paper. |
| Impact | Co-author on paper. |
| Start Year | 2016 |
| Description | Ana Cvejic - Wellcome Sanger Institute |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI Ana Cvejic - Collaborative project |
| Collaborator Contribution | Collaboration with Omer Ali Bayraktar at the Wellcome Trust Sanger Institute. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Andrew McCaskis - UKRMP |
| Organisation | UK Regenerative Medicine Platform |
| Department | Engineered Cell Environment Hub |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | UK Regenerative Medicine Platform Hub - Engineered Cell Environment |
| Collaborator Contribution | UK Regenerative Medicine Platform Hub - Engineered Cell Environment |
| Impact | None yet |
| Start Year | 2018 |
| Description | Anna Philpott - CRUK CI |
| Organisation | Cancer Research UK Cambridge Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Anna Philpott; Chipseq/RNAseq analysis of transcriptional regulators of stemness/differentiation. |
| Collaborator Contribution | Collaboration with Jason Carroll; Chipseq/RNAseq analysis of transcriptional regulators of stemness/differentiation. |
| Impact | Chipseq/RNAseq analysis of transcriptional regulators of stemness/differentiation. |
| Start Year | 2012 |
| Description | Anna Philpott - Gurdon |
| Organisation | University of Cambridge |
| Department | Gurdon Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Anna Philpott;; Transcriptional dynamics. |
| Collaborator Contribution | Collaboration with John Gurdon; Transcriptional dynamics. |
| Impact | Transcriptional dynamics. |
| Start Year | 2011 |
| Description | Anna Philpott - Harvard Medical School |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Anna Philpott; Mathematical modelling of transcriptional dynamics. |
| Collaborator Contribution | Collaboration with Jeremy Gunawardena; Mathematical modelling of transcriptional dynamics. |
| Impact | Mathematical modelling of transcriptional dynamics. |
| Start Year | 2010 |
| Description | Anna Philpott - Harvard Medical School |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Anna Philpott; Mathematical modelling of transcriptional dynamics. |
| Collaborator Contribution | Collaboration with Jeremy Gunawardena; Mathematical modelling of transcriptional dynamics. |
| Impact | Mathematical modelling of transcriptional dynamics. |
| Start Year | 2010 |
| Description | Anna Philpott - Harvard Stem Cell Institute |
| Organisation | Harvard University |
| Department | Harvard Stem Cell Institute |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Anna Philpott; Collaborator on an MRC grant on islet cell formation in the pancreas. |
| Collaborator Contribution | Collaboration with Doug Melton.; Collaborator on an MRC grant on islet cell formation in the pancreas. |
| Impact | Collaborator on an MRC grant on islet cell formation in the pancreas. |
| Start Year | 2013 |
| Description | Austin Smith - AstraZeneca |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Austin Smith; Advisory Board. |
| Collaborator Contribution | Collaboration with Lorenz Mayr; Advisory Board. |
| Impact | Advisory Board. |
| Start Year | 2015 |
| Description | Austin Smith - Cell Therapy Catapult |
| Organisation | Cell Therapy Catapult |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Austin Smith; Advisory Board. |
| Collaborator Contribution | Collaboration with Johan Hyllner; Adviosry Board. |
| Impact | Advisory Board. |
| Start Year | 2014 |
| Description | Austin Smith - Microsoft Research |
| Organisation | Microsoft Research |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: Austin Smith; Computational Modelling. |
| Collaborator Contribution | Collaboration with Stephen Emmott and Sara-Jane Dunn; Computational modelling. |
| Impact | Computational modelling; Joint publications. |
| Start Year | 2013 |
| Description | Austin Smith - PSCP |
| Organisation | Loughborough University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Austin Smith; The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Collaborator Contribution | The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Impact | The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Start Year | 2013 |
| Description | Austin Smith - PSCP |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Austin Smith; The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Collaborator Contribution | The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Impact | The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Start Year | 2013 |
| Description | Austin Smith - Ramiro Alberio |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Pluripotency in sheep and pig |
| Collaborator Contribution | Pluripotency in sheep and pig |
| Impact | None yet |
| Start Year | 2018 |
| Description | Austin Smith - StemCell Technologies |
| Organisation | Stemcell Technologies |
| Country | Canada |
| Sector | Private |
| PI Contribution | CSCI PI: Austin Smith; Partner in EC project plus licensing agreement. |
| Collaborator Contribution | Collaboration with Sharon Louis and Allen Eaves; Partner in EC project plus licensing agreement. |
| Impact | Partner in EC project plus licensing agreement. |
| Start Year | 2014 |
| Description | BK Koo - Sanger |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Bon-Kyoung Koo; We will look into single cell transcriptomics of Troy+ stomach stem cells. Sanger will use the funds under this RRC to carry out single cell sorting and RCA sequencing of 10 stomach stem cell samples provided by Cambridge, and both parties will collaborate on the analysis of the data. |
| Collaborator Contribution | Collaboration with John Marioni; We will look into single cell transcriptomics of Troy+ stomach stem cells. Sanger will use the funds under this RRC to carry out single cell sorting and RCA sequencing of 10 stomach stem cell samples provided by Cambridge, and both parties will collaborate on the analysis of the data. |
| Impact | We will look into single cell transcriptomics of Troy+ stomach stem cells. Sanger will use the funds under this RRC to carry out single cell sorting and RCA sequencing of 10 stomach stem cell samples provided by Cambridge, and both parties will collaborate on the analysis of the data. |
| Start Year | 2016 |
| Description | BK Koo - University Carl Gustav Carus |
| Organisation | University Hospital Carl Gustav Carus Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bon-Kyoung Koo; ERC Starting Grant. |
| Collaborator Contribution | Collaboration with Daniel Stange. |
| Impact | Joint meeting for developing placenta and endometrium organoids. |
| Start Year | 2014 |
| Description | BK Koo - University of Cambridge (Centre for Trophoblast Research) |
| Organisation | University of Cambridge |
| Department | Department of Haematology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bon-Kyoung Koo; Joint meeting for developing placenta and endometrium organoids. |
| Collaborator Contribution | Collaboration with Graham Burton and Ashley Moffett; Joint meeting for developing placenta and endometrium organoids. |
| Impact | Joint meeting for developing placenta and endometrium organoids. |
| Start Year | 2014 |
| Description | Ben Simons - Danstem |
| Organisation | University of Copenhagen |
| Department | Psychiatric Center Copenhagen |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Development of the mouse intestinal epithelium and development of epidermal appendages. |
| Collaborator Contribution | Collaboration with Kim Jensen; Development of the mouse intestinal epithelium and development of epidermal appendages. |
| Impact | Development of the mouse intestinal epithelium and development of epidermal appendages. |
| Start Year | 2016 |
| Description | Ben Simons - Hospital for Sick Children |
| Organisation | The Hospital for Sick Children (SickKids) |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Ben Simons; Dynamics of tumour propagating cells in medullablastoma and gioblastoma. |
| Collaborator Contribution | Collaboration with Peter Dirks; Dynamics of tumour propagating cells in medullablastoma and gioblastoma. |
| Impact | Dynamics of tumour propagating cells in medullablastoma and gioblastoma. |
| Start Year | 2013 |
| Description | Ben Simons - Hubrecht Institute |
| Organisation | Royal Netherlands Academy of Arts and Sciences |
| Department | Hubrecht Institute |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Maintenance of the intestinal epithelium and development of the mammary epithelium. |
| Collaborator Contribution | Collaboration with Jacco van Rheenen; Maintenance of the intestinal epithelium and development of the mammary epithelium. |
| Impact | Maintenance of the intestinal epithelium and development of the mammary epithelium. |
| Start Year | 2013 |
| Description | Ben Simons - Hubrecht Institute |
| Organisation | Royal Netherlands Academy of Arts and Sciences |
| Department | Hubrecht Institute |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Maintenance of the adult subventricular zone. |
| Collaborator Contribution | Collaboration with Hans Clevers; Maintenance of the adult subventricular zone. |
| Impact | Maintenance of the adult subventricular zone. |
| Start Year | 2010 |
| Description | Ben Simons - John Hopkins Medical School |
| Organisation | Johns Hopkins University |
| Department | School of Medicine Johns Hopkins |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Maintenance of the adult subgranular zone. |
| Collaborator Contribution | Collaboration with Hongjun Song; Maintenance of the adult subgranular zone. |
| Impact | Maintenance of the adult subgranular zone. |
| Start Year | 2012 |
| Description | Ben Simons - Memorial Sloane Kettering Cancer Center |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Development of mouse neocortex. |
| Collaborator Contribution | Collaboration with Songhai Shi; Development of mouse neocortex. |
| Impact | Development of mouse neocortex. |
| Start Year | 2013 |
| Description | Ben Simons - National Institute for Basic Biology |
| Organisation | Ministry of the Environment |
| Department | National Institute for Basic Biology (NIBB) |
| Country | Japan |
| Sector | Public |
| PI Contribution | CSCI PI: Ben Simons; Spermatogenesis in mouse. |
| Collaborator Contribution | Collaboration with Shosei Yoshida; Spermatogenesis in mouse. |
| Impact | Spermatogenesis in mouse. |
| Start Year | 2009 |
| Description | Ben Simons - Universite Libre de Bruxelles |
| Organisation | University Libre Bruxelles (Université Libre de Bruxelles ULB) |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Mechanisms of development and tumour initiation in epidermis. |
| Collaborator Contribution | Collaboration with Cedric Blanpain; Mechanisms of development and tumour initiation in epidermis. |
| Impact | Mechanisms of development and tumour initiation in epidermis. Several publications. |
| Start Year | 2011 |
| Description | Ben Simons - University College London |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Maintenance of human airways. |
| Collaborator Contribution | Collaboration with Samuel Janes; Maintenance of human airways. |
| Impact | Maintenance of human airways. |
| Start Year | 2012 |
| Description | Ben Simons - University of Cambridge (PDN) |
| Organisation | University of Cambridge |
| Department | Department of Psychology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Development of zebrafish retina. |
| Collaborator Contribution | Collaboration with William Harris; Development of zebrafish retina. |
| Impact | Development of zebrafish retina. |
| Start Year | 2011 |
| Description | Bertie Gottgens - Allon Klein |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Single cell studies |
| Collaborator Contribution | Single cell studies |
| Impact | None yet |
| Start Year | 2018 |
| Description | Bertie Gottgens - Autolus |
| Organisation | Autolus Limited |
| Department | Autolus |
| Country | Poland |
| Sector | Private |
| PI Contribution | CSCI PI: Bertie Gottgens; Single cell genomics analysis of CAR-T cells. |
| Collaborator Contribution | Collaboration with Nina Kotsopoulou; Single cell genomics analysis of CAR-T cells. |
| Impact | Single cell genomics analysis of CAR-T cells. |
| Start Year | 2016 |
| Description | Bertie Gottgens - Baylor College of Medicine |
| Organisation | Baylor College of Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with Peggy Goodell; Joint research papers. |
| Impact | Joint research papers. |
| Start Year | 2014 |
| Description | Bertie Gottgens - Centro de Medicina Regenerativa de Barcelona |
| Organisation | Center of Regenerative Medicine in Barcelona |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Bertie Gottgens; RNA-Seq. |
| Collaborator Contribution | Collaboration with Alessandra Giorgetti; RNA-seq |
| Impact | RNA-seq. |
| Start Year | 2016 |
| Description | Bertie Gottgens - David Bryder |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens - Joint research paper. |
| Collaborator Contribution | Collaboration with David Bryder - Joint research paper. |
| Impact | Joint research paper. |
| Start Year | 2017 |
| Description | Bertie Gottgens - Dresden |
| Organisation | Technical University of Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens. |
| Collaborator Contribution | Collaboration with Claudia Waskow. |
| Impact | None yet. |
| Start Year | 2016 |
| Description | Bertie Gottgens - EBI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with John Marioni; Joint research papers. |
| Impact | Joint research papers. |
| Start Year | 2015 |
| Description | Bertie Gottgens - Elaine Dzierzak |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Single cell studies. Joint research paper |
| Collaborator Contribution | Single cell studies. Joint research paper |
| Impact | Joint research paper |
| Start Year | 2018 |
| Description | Bertie Gottgens - Fiona Gribble |
| Organisation | University of Cambridge |
| Department | Department of Clinical Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens - Joint research paper. |
| Collaborator Contribution | Collaboration with Fiona Gribble - joint research paper. |
| Impact | Joint research paper. |
| Start Year | 2017 |
| Description | Bertie Gottgens - GSK |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: Bertie Gottgens; Single cell profiling of gene therapy products. |
| Collaborator Contribution | Single cell profiling of gene therapy products. |
| Impact | Single cell profiling of gene therapy products. |
| Start Year | 2016 |
| Description | Bertie Gottgens - Hui Zhang |
| Organisation | Chinese Academy of Sciences |
| Department | Shenzhen Institute of Advanced Integration Technology |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Training in research techniques |
| Collaborator Contribution | Training in research techniques |
| Impact | None yet |
| Start Year | 2018 |
| Description | Bertie Gottgens - KJ Patel |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Laboratory of Molecular Biology (LMB) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Single cell studies |
| Collaborator Contribution | Single cell studies |
| Impact | None yet |
| Start Year | 2018 |
| Description | Bertie Gottgens - Larissa Carnevalli |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Joint research project on Acute Myeloid Leukaemia |
| Collaborator Contribution | Joint research project on Acute Myeloid Leukaemia |
| Impact | None yet. |
| Start Year | 2018 |
| Description | Bertie Gottgens - Novo Nordisk |
| Organisation | Novo Nordisk |
| Country | Denmark |
| Sector | Private |
| PI Contribution | Study (covered by CDA) of embryonic blood cell development |
| Collaborator Contribution | Study (covered by CDA) of embryonic blood cell development |
| Impact | None yet |
| Start Year | 2019 |
| Description | Bertie Gottgens - Ross Hardison |
| Organisation | Penn State University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint National Institutes of Health grant |
| Collaborator Contribution | Collaboration with Ross Hardison - Joint National Institutes of Health grant. |
| Impact | Joint National Institutes of Health grant |
| Start Year | 2017 |
| Description | Bertie Gottgens - Sheba Medical Centre |
| Organisation | Sheba Medical Centre |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with Shai Izraeli; Joint research papers. |
| Impact | Joint research papers. |
| Description | Bertie Gottgens - Thomas Mercher |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens - Single cell analysis |
| Collaborator Contribution | Collaboration with Thomas Mercher - Single cell analysis |
| Impact | Single cell analysis. |
| Start Year | 2017 |
| Description | Bertie Gottgens - University of Birmigham |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Joint research papers. Joint BBSRC LoLa Award. |
| Collaborator Contribution | Collaboration with Constanze Bonifer, Georges Lacaud and Valeirie Kouskoff; Joint research papers. Joint BBSRC LoLa Award |
| Impact | Joint research papers. Joint BBSRC LoLa Award. |
| Start Year | 2011 |
| Description | Bertie Gottgens - University of Birmigham |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Joint research papers. Joint BBSRC LoLa Award. |
| Collaborator Contribution | Collaboration with Constanze Bonifer, Georges Lacaud and Valeirie Kouskoff; Joint research papers. Joint BBSRC LoLa Award |
| Impact | Joint research papers. Joint BBSRC LoLa Award. |
| Start Year | 2011 |
| Description | Bertie Gottgens - University of California San Francisco |
| Organisation | University of California, San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint publication. |
| Collaborator Contribution | Collaboration with Emanuelle Passegue; Joint publication. |
| Impact | Joint publication. |
| Start Year | 2016 |
| Description | Bertie Gottgens - University of Cambridge (Genetics) |
| Organisation | University of Cambridge |
| Department | Department of Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with Boris Adryan; Joint research papers. |
| Impact | Joint research papers. |
| Start Year | 2015 |
| Description | Bertie Gottgens - University of New South Wales |
| Organisation | University of New South Wales |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaborations with John Pimanda; Joint research papers. |
| Impact | Joint research papers. |
| Start Year | 2007 |
| Description | Bertie Gottgens - University of Oxford |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Single cell analysis. |
| Collaborator Contribution | Collaboration with John Todd; Single cell analysis. |
| Impact | Single cell analysis. None yet. |
| Start Year | 2016 |
| Description | Bertie Gottgens - Vrifje University of Amsterdam |
| Organisation | Free University of Amsterdam |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with Nicola Bonzanni; Joint research papers |
| Impact | Joint research papers. |
| Start Year | 2008 |
| Description | Bertie Gottgens - WIMM |
| Organisation | University of Oxford |
| Department | Weatherall Institute of Molecular Medicine (WIMM) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with Marella de Brujin; Joint research papers. |
| Impact | Joint research papers. |
| Start Year | 2007 |
| Description | Brian Hendrich - EMBL |
| Organisation | European Molecular Biology Laboratory |
| Department | EMBL-Grenoble |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Collaboration on NuRD structure. Co-PI on EU FP7 Grant. |
| Collaborator Contribution | Collaboration with Imre Berger; Collaboration on NuRD structure. Co-PI on EU FP7 Grant. |
| Impact | Collaboration on NuRD structure. Co-PI on EU FP7 Grant. |
| Start Year | 2013 |
| Description | Brian Hendrich - European Institute of Oncology |
| Organisation | European Institute of Oncology (IEO) |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Collaborative small molecule screens. Co-PI on EU FP7 grant. |
| Collaborator Contribution | Collaboration with Saverio Minucci; Collaborative small molecule screens. Co-PI on EU FP7 grant. |
| Impact | Collaborative small molecule screens. Co-PI on EU FP7 grant. |
| Start Year | 2012 |
| Description | Brian Hendrich - MRC CSC |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Clinical Sciences Centre (CSC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | CSCI PI: Brian Hendrich; Joint authored paper submitted. |
| Collaborator Contribution | Collaboration with Matthias Merkenschlager; Joint authored paper submitted. |
| Impact | Joint authored paper submitted. |
| Start Year | 2015 |
| Description | Brian Hendrich - Sandra Hake |
| Organisation | Justus Liebig University Giessen |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich - Investigation of Mta protein function: one joint publication in preparation |
| Collaborator Contribution | Collaboration with Sandra Hake - Investigation of Mta protein function: one joint publication in preparation |
| Impact | Investigation of Mta protein function: one joint publication in preparation. |
| Start Year | 2016 |
| Description | Brian Hendrich - Trinity College Dublin |
| Organisation | Trinity College Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Function of chromatin remodellers in development and cancer. Joint grant application planned. |
| Collaborator Contribution | Collaboration with Adrian Bracken; Function of chromatin remodellers in development and cancer. Joint grant application planned. |
| Impact | Function of chromatin remodellers in development and cancer. Joint grant application planned. |
| Start Year | 2015 |
| Description | Brian Hendrich - University Medical Centre Utrecht |
| Organisation | University Medical Center Utrecht (UMC) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Collaborative investigation into protein complex structure. Co-PI on EU FP7 Grant, one joint paper published. |
| Collaborator Contribution | Collaboration with Michiel Vermeulen; Collaborative investigation into protein complex structure. Co-PI on EU FP7 Grant, one joint paper published. |
| Impact | Collaborative investigation into protein complex structure. Co-PI on EU FP7 Grant, one joint paper published |
| Start Year | 2013 |
| Description | Brian Hendrich - University of Cambridge (Biochemistry - Lilley) |
| Organisation | University of Cambridge |
| Department | Department of Chemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Collaborative research, named on her grant applications. |
| Collaborator Contribution | Collaboration with Kathryn Lilley; Collaborative research, named on her grant applications. |
| Impact | Collaborative research, named on her grant applications. |
| Start Year | 2014 |
| Description | Brian Hendrich - University of Cambridge (Biochemistry) |
| Organisation | University of Cambridge |
| Department | Department of Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; One EU FP7 grant awarded to us both, I am named collaborator on one grant and other applications. Ongoing technology development , one joint paper published. |
| Collaborator Contribution | Collaboration with Ernest Laue; One EU FP7 grant awarded to us both, I am named collaborator on one grant and other applications. Ongoing technology development , one joint paper published. |
| Impact | One EU FP7 grant awarded to us both, I am named collaborator on one grant and other applications. Ongoing technology development , one joint paper published. |
| Start Year | 2009 |
| Description | Brian Hendrich - University of Dundee |
| Organisation | University of Dundee |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with Greg Findlay of the University of Dundee |
| Impact | Grant application outcome unknown |
| Start Year | 2020 |
| Description | Brian Hendrich - University of Edinburgh |
| Organisation | University of Edinburgh |
| Department | Centre for Discovery Brain Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with John Mason of the University of Edinburgh's Centre for Discovery Brain Sciences. |
| Impact | Grant application outcome unknown |
| Start Year | 2020 |
| Description | Brian Hendrich - University of Edinburgh |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Joint research efforts, one joint group meeting in Edinburgh, discussing grant options. |
| Collaborator Contribution | Collaboration with Adrian Bird; Joint research efforts, one joint group meeting in Edinburgh, discussing grant options. |
| Impact | Joint research efforts, one joint group meeting in Edinburgh, discussing grant options. |
| Start Year | 2014 |
| Description | Brian Hendrich - University of Kumamoto |
| Organisation | University of Kumamoto |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Mice supplied, one joint paper published. |
| Collaborator Contribution | Collaboration with Ryuichi Nishinakamura; Mice supplied, one joint paper published. |
| Impact | Mice supplied, one joint paper published. |
| Start Year | 2012 |
| Description | Brian Hendrich - University of Oslo |
| Organisation | University of Oslo |
| Department | Institute of Basic Medical Sciences |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with Gareth Sullivan of the University of Oslo's Institute of Basic Medical Sciences. |
| Impact | Grant application outcome unknown |
| Start Year | 2020 |
| Description | Brian Hendrich - University of Sussex |
| Organisation | University of Sussex |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Investigating DNA repair function of CHD4. |
| Collaborator Contribution | Collaboration with Jessica Downs; Investigating DNA repair function of CHD4. |
| Impact | Investigating DNA repair function of CHD4. |
| Start Year | 2014 |
| Description | Brian Hendrich - Washington University in St. Louis |
| Organisation | Washington University in St Louis |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with Sabine Dietman of the Washington University (St Louis) School of Medicine. |
| Impact | Application outcome unknown |
| Start Year | 2020 |
| Description | Brian Huntly - Babraham Institute |
| Organisation | Babraham Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project |
| Collaborator Contribution | Collaborative project with Wolf Reik of Babraham Institute's Epigenetics lab. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Brian Huntly - Centre for Genomic Regulation |
| Organisation | Centre for Genomic Regulation (CRG) |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project |
| Collaborator Contribution | Collaboration with Marc Marti-Renom of the Centre for Genomic Regulation |
| Impact | Outcomes expected 2021 |
| Start Year | 2020 |
| Description | Brian Huntly - David Adams |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Brian Huntly - Joint papers |
| Collaborator Contribution | Collaboration with David Adams - joint papers. |
| Impact | Joint papers. |
| Start Year | 2017 |
| Description | Brian Huntly - Denis Calado, Jude Fitzgibbon, Jessica Okusun |
| Organisation | Francis Crick Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly - academic collaboration |
| Collaborator Contribution | Collaboration with Denis Calado, Jude Fitzgibbon, Jessica Okusun. |
| Impact | Academic collaboration - ongoing. |
| Start Year | 2017 |
| Description | Brian Huntly - GSK |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: Brian Huntly; Mechanistic, pre-clinical investigation of BET inhibitors. |
| Collaborator Contribution | Collaboration with Rab Prinjha; Mechanistic, pre-clinical investigation of BET inhibitors. |
| Impact | Mechanistic, pre-clinical investigation of BET inhibitors. |
| Start Year | 2013 |
| Description | Brian Huntly - GSK Cancer Epigenetics DPU |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: Brian Huntly; Translational collaboration re experimental therapeutics. |
| Collaborator Contribution | Collaboration with Peter Tumino; Translational collaboration re experimental therapeutics. |
| Impact | Translational collaboration re experimental therapeutics. |
| Start Year | 2012 |
| Description | Brian Huntly - Institut Gustave Roussy |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project |
| Collaborator Contribution | Collaboration with Thomas Mercher of l'Institut Gustave Roussy |
| Impact | Outcomes expected 2021 |
| Start Year | 2020 |
| Description | Brian Huntly - John Pimanda |
| Organisation | University of New South Wales |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly - Joint papers. |
| Collaborator Contribution | Collaboration with John Pimanda - joint papers. |
| Impact | Joint papers. |
| Start Year | 2015 |
| Description | Brian Huntly - Kings College London |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Academic collaboration. |
| Collaborator Contribution | Collaboration with Cameron Osbourne; Academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2014 |
| Description | Brian Huntly - MRC Cancer Unit |
| Organisation | University of Cambridge |
| Department | MRC Cancer Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Academic collaboration. |
| Collaborator Contribution | Collaboration with Christian Frezza; Academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2012 |
| Description | Brian Huntly - Ming Du |
| Organisation | University of Cambridge |
| Department | Department of Pathology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly - Joint papers |
| Collaborator Contribution | Collaboration with Ming-Qing Du - joint papers. |
| Impact | Joint papers. |
| Start Year | 2017 |
| Description | Brian Huntly - Nigel Brooks |
| Organisation | CellCentric Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Brian Huntly - Investigation of CREBBP/p300 inhibitor. |
| Collaborator Contribution | Collaboration with Nigel Brooks - Investigation of CREBBP/p300 inhibitor. |
| Impact | Investigation of CREBBP/p300 inhibitor. |
| Start Year | 2017 |
| Description | Brian Huntly - Pfizer |
| Organisation | Pfizer Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Brian Huntly; Translational collaboration re experimental therapeutics. |
| Collaborator Contribution | Collaboration with Kevin Lee; Translational collaboration re experimental therapeutics. |
| Impact | Translational collaboration re experimental therapeutics. |
| Start Year | 2012 |
| Description | Brian Huntly - Radek Skoda |
| Organisation | University Hospital Basel |
| Country | Switzerland |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Brian Huntly - Academic collaboration |
| Collaborator Contribution | Collaboration with Radek Skoda - academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2017 |
| Description | Brian Huntly - Ulrich Steidl |
| Organisation | Albert Einstein College of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly - academic collaboration. |
| Collaborator Contribution | Collaboration with Ulrich Steidl - academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2017 |
| Description | Brian Huntly - University of Cambridge (Gurdon) |
| Organisation | National Institute for Health Research |
| Department | NIHR Cambridge Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Academic collaboration. |
| Collaborator Contribution | Collaboration with Tony Kouzarides. |
| Impact | Academic collaboration. |
| Start Year | 2010 |
| Description | Brian Huntly - University of Copenhagen |
| Organisation | University of Copenhagen |
| Department | Department of Veterinary Disease Biology |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Generation of acetylation target datasets. |
| Collaborator Contribution | Collaboration with Chuna Ram Choudhary; Generation of acetylation target datasets. |
| Impact | Generation of acetylation target datasets. |
| Start Year | 2013 |
| Description | Brian Huntly - University of Edinburgh |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Academic collaboration. |
| Collaborator Contribution | Collaboration with KAtrin Ottersbach; Academic collaboration. |
| Impact | Joint paper; Academic collaboration. |
| Start Year | 2008 |
| Description | Brian Huntly - University of Edinburgh |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Academic collaboration. |
| Collaborator Contribution | Collaboration with KAtrin Ottersbach; Academic collaboration. |
| Impact | Joint paper; Academic collaboration. |
| Start Year | 2008 |
| Description | Brian Huntly - University of Navarra |
| Organisation | University of Navarra Clinic |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project and joint grant application |
| Collaborator Contribution | Collaboration and joint grant application with Felipe Prosper of University of Navarra Clinic. |
| Impact | Outcomes expected later in 2021 |
| Start Year | 2020 |
| Description | Cedric Ghevaert - AstraZeneca |
| Organisation | AstraZeneca |
| Department | AstraZeneca Sweden |
| Country | Sweden |
| Sector | Private |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ryan Hicks at AstraZeneca Sweden involving university stem cells. |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - DefiniGEN |
| Organisation | DefiniGEN |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Cedric Ghevaert; Discussions around licence for megakaryocyte patent. |
| Collaborator Contribution | Collaboration with Marcus Yeo; Discussions around licence for megakaryocyte patent. |
| Impact | Discussions around licence for megakaryocyte patent. |
| Start Year | 2016 |
| Description | Cedric Ghevaert - Platelet Biogenesis |
| Organisation | University of Hawaii |
| Department | Institute for Biogenesis Research |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Cedric Ghevaert; Discussions around licence for megakaryocyte patent. |
| Collaborator Contribution | Collaboration with Jonathon Thon; Discussions around licence for megakaryocyte patent. |
| Impact | Discussions around licence for megakaryocyte patent. |
| Start Year | 2016 |
| Description | Cedric Ghevaert - Platod |
| Organisation | PLATOD |
| Country | France |
| Sector | Private |
| PI Contribution | CSCI PI: Cedric Ghevaert. Discussions around licence for megakaryocyte patent. |
| Collaborator Contribution | Collaboration with Dominic Baruch; Discussions around licence for megakaryocyte patent. |
| Impact | Discussions around licence for megakaryocyte patent. |
| Start Year | 2016 |
| Description | Cedric Ghevaert - Rockend, LTD |
| Organisation | University of Cambridge |
| Department | Milner Therapeutics Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Shaun Foy and Rodger Novak of Rockend, Ltd, titled "Production of platelet-like particles in vitro for therapeutics." |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - Ruth Cameron and Serena Best |
| Organisation | University of Cambridge |
| Department | Department of Materials Science & Metallurgy |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Cedric Ghevaert; Bioscaffold |
| Collaborator Contribution | Collaboration with Ruth Cameron and Serena Best - bioscaffold |
| Impact | Bioscaffold |
| Start Year | 2014 |
| Description | Cedric Ghevaert - University College London - University of Edinburgh |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Wasim Qaseem of University College London and Stuart Forbes of the University of Edinburgh entitled "Immunology Project (UKRMP to UCL) - Universal cells to overcome HLA barriers in regenerative medicine". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - University College London - University of Edinburgh |
| Organisation | University of Edinburgh |
| Department | MRC Centre for Regenerative Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Wasim Qaseem of University College London and Stuart Forbes of the University of Edinburgh entitled "Immunology Project (UKRMP to UCL) - Universal cells to overcome HLA barriers in regenerative medicine". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - University of Bristol |
| Organisation | University of Bristol |
| Department | School of Physiology, Pharmacology and Neuroscience |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Alastair Poole of University of Bristol titled "Biogenesis and Bioengineering of Human Platelets." |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - University of Cambridge Material Science |
| Organisation | University of Cambridge |
| Department | Department of Materials Science & Metallurgy |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Sohini Kar-Narayan of the University of Cambridge Department of Materials Science & Metallurgy. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute |
| Organisation | Babraham Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2018 |
| Description | Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute |
| Organisation | Loughborough University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2018 |
| Description | Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute |
| Organisation | University of Sheffield |
| Department | Department of Biomedical Science |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2018 |
| Description | Dan Hodso - Markus Meuler |
| Organisation | PhoreMost |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Collaboration with Phoremost to use human protein domain library to screen to identify therapeutic strategies to target the OCT2-OCA-B interface. |
| Collaborator Contribution | Collaboration with Phoremost to use human protein domain library to screen to identify therapeutic strategies to target the OCT2-OCA-B interface. |
| Impact | None yet |
| Start Year | 2018 |
| Description | Dan Hodson - Babraham |
| Organisation | Babraham Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Dan Hodson; Collaborative research. |
| Collaborator Contribution | Collaboration with David Turner; Collaborative research. |
| Impact | None yet |
| Start Year | 2013 |
| Description | David Kent - EBI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: David Kent; Machine Learning and quantitative biology. |
| Collaborator Contribution | Collaboration with Florian Buttner;Machine Learning and quantitative biology. |
| Impact | Machine Learning and quantitative biology. |
| Start Year | 2015 |
| Description | David Kent - GSK |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: David Kent; GSK / BBSRC CASE Studentship (M Shepherd) - quantitative and systems biology. |
| Collaborator Contribution | Collaboration with Armin Sepp; GSK / BBSRC CASE Studentship (M Shepherd) - quantitative and systems biology. |
| Impact | GSK / BBSRC CASE Studentship (M Shepherd) - quantitative and systems biology. |
| Start Year | 2016 |
| Description | David Kent - Leon Lin |
| Organisation | Stemcell Technologies |
| Country | Canada |
| Sector | Private |
| PI Contribution | STEMCELL Technologies reagent testing |
| Collaborator Contribution | STEMCELL Technologies reagent testing |
| Impact | None yet |
| Start Year | 2018 |
| Description | David Kent - Memorial Sloan Kettering |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: David Kent; Sequencing and clinical genomics. |
| Collaborator Contribution | Collaboration with Elli Papaemmanuil; Sequencing and clinical genomics. |
| Impact | Sequencing and clinical genomics. |
| Start Year | 2013 |
| Description | David Kent - Mike Stratton |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Genomics signatures in cancer |
| Collaborator Contribution | Genomics signatures in cancer |
| Impact | None yet. |
| Start Year | 2018 |
| Description | David Kent - University of British Columbia |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CSCI PI: David Kent; Reagents and knowledge transfer. |
| Collaborator Contribution | Collaboration with Connie Eaves; Reagents and knowledge transfer. |
| Impact | Reagents and knowledge transfer. |
| Description | David Kent - Weizmann Institute |
| Organisation | Weizmann Institute of Science |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | CSCI PI: David Kent; Asymmetric Division of HSCs. |
| Collaborator Contribution | Collaborationwith Tsvee Lapidot; Asymmetric Division of HSCs. |
| Impact | Asymmetric Division of HSCs. |
| Start Year | 2015 |
| Description | David Rowitch - StemCells Inc |
| Organisation | StemCells, Inc. |
| Country | United States |
| Sector | Private |
| PI Contribution | CSCI PI: David Rowitch; Collaborative research. |
| Collaborator Contribution | Collaborative research. |
| Impact | Collaborative research. |
| Start Year | 2010 |
| Description | Deep Sequencing |
| Organisation | Radboud University Nijmegen Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Deep Sequencing |
| Collaborator Contribution | Deep Sequencing |
| Impact | n/a |
| Start Year | 2011 |
| Description | EBI / SCI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Deep sequence analysis |
| Collaborator Contribution | Deep sequence analysis |
| Impact | Publication: Identification of the missing pluripotency mediator downstream of leukaemia inhibitory |
| Start Year | 2011 |
| Description | ESTOOLS |
| Organisation | Academy of Sciences of the Czech Republic |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Babraham Institute |
| Department | Stem Cell Sciences UK Ltd |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Bellvitge Biomedical Research Institute |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Hebrew University of Jerusalem |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Netherlands Cancer Institute (NKI) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Stem Cell Technologies |
| Country | Canada |
| Sector | Private |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Tampere University of Technology |
| Country | Finland |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Technical University of Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Basel |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Bonn |
| Department | Medical Centre Bonn |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Helsinki |
| Country | Finland |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Milan |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Turku |
| Country | Finland |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Babraham Institute |
| Department | Stem Cell Sciences UK Ltd |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Cancer Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | European Molecular Biology Laboratory |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | NeuroNova AB |
| Country | Sweden |
| Sector | Private |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | NsGene A/S |
| Country | Denmark |
| Sector | Private |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Pasteur Institute, Paris |
| Country | France |
| Sector | Charity/Non Profit |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | San Raffaele Hospital |
| Department | Stem Cell Research Institute |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Swiss Federal Institute of Technology in Lausanne (EPFL) |
| Country | Switzerland |
| Sector | Public |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | University of Bonn |
| Department | Medical Centre Bonn |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | University of Milan |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | Elisa Laurenti - EPFL |
| Organisation | Swiss Federal Institute of Technology in Lausanne (EPFL) |
| Country | Switzerland |
| Sector | Public |
| PI Contribution | CSCI PI: Elisa Laurenti; Joint publications. |
| Collaborator Contribution | Collaboration with Didier Trono; Joint publications. |
| Impact | Joint publications. |
| Start Year | 2007 |
| Description | Elisa Laurenti - Hitoshi Takizawa |
| Organisation | Kumamoto University |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti - Studying adult human haematopoietic stem cells using a humanised bone marrow environment. |
| Collaborator Contribution | Collaboration with Hitoshi Takizawa - Studying adult human haematopoietic stem cells using a humanised bone marrow environment. |
| Impact | Studying adult human haematopoietic stem cells using a humanised bone marrow environment. |
| Start Year | 2017 |
| Description | Elisa Laurenti - Liran Shlush |
| Organisation | Weizmann Institute of Science |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti - Functional effects of preleukaemic mutations on human haematopoietic stem cells. |
| Collaborator Contribution | Collaboration with Liran Shlush - Functional effects of preleukaemic mutations on human haematopoietic stem cells. |
| Impact | Functional effects of preleukaemic mutations on human haematopoietic stem cells. |
| Start Year | 2017 |
| Description | Elisa Laurenti - Max Planck Institute of Immunobiology and Epigenetics |
| Organisation | Max Planck Society |
| Department | Max Planck Institute of Immunobiology and Epigenetics |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI Elisa Laurenti - Collaborative project |
| Collaborator Contribution | Collaboration with Nina Cabezas-Wallscheid entitled "Molecular regulation of human haematopoietic stem cell quiescence." |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Elisa Laurenti - Peter Campbell |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Age-related changes in human haematopoietic stem cells at single cell and population levels |
| Collaborator Contribution | Age-related changes in human haematopoietic stem cells at single cell and population levels |
| Impact | None yet |
| Start Year | 2018 |
| Description | Elisa Laurenti - Universite Paris Descartes |
| Organisation | University of Paris - Descartes |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti; The transcriptional programmes of T-Acute Lymphoblastic Leukaemia. |
| Collaborator Contribution | Collaboration with Elizabeth Macintyre; The transcriptional programmes of T-Acute Lymphoblastic Leukaemia. |
| Impact | The transcriptional programmes of T-Acute Lymphoblastic Leukaemia. |
| Start Year | 2015 |
| Description | Elisa Laurenti - University Health Network |
| Organisation | University Health Network (UHN) |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti; Joint publications. |
| Collaborator Contribution | Collaboration with John Dick; Joint publications. |
| Impact | Joint publications. |
| Start Year | 2014 |
| Description | Elisa Laurenti - University of Cambridge (Haematology) |
| Organisation | UK Clinical Research Collaboration |
| Department | Centre for Diet and Activity Research (CEDAR) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti; Effects of inflammation on HSC; study of adult human HSC. |
| Collaborator Contribution | Collaboration with Willem Ouwehand and Mattia Frontini; Effects of inflammation on HSC; study of adult human HSC. |
| Impact | Effects of inflammation on HSC; study of adult human HSC. |
| Start Year | 2014 |
| Description | Elisa Laurenti - University of Cambridge (Surgery) |
| Organisation | University of Cambridge |
| Department | Department of Engineering |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti; Study of adult human HSC and their cryopreservation. |
| Collaborator Contribution | Collaboration with Kouroush Saeb-Parsy.; Study of adult human HSC and their cryopreservation. |
| Impact | Study of adult human HSC and their cryopreservation. |
| Start Year | 2015 |
| Description | Elisa Laurenti, Bertie Gottgens - Muzlifah Haniffa |
| Organisation | Newcastle University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Decoding the blood and immune systems development during human fetal liver haematopoiesis |
| Collaborator Contribution | Decoding the blood and immune systems development during human fetal liver haematopoiesis |
| Impact | None yet |
| Start Year | 2018 |
| Description | Euratrans |
| Organisation | Academy of Sciences of the Czech Republic |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Alternative Energies and Atomic Energy Commission (CEA) |
| Country | France |
| Sector | Public |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | European Molecular Biology Laboratory |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Helmholtz Association of German Research Centres |
| Department | The Max Delbrück Center for Molecular Medicine (MDC) |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Max Planck Society |
| Department | Max Planck Institute of Biochemistry |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Medical College of Wisconsin |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Research Network Services (RNSL) Ltd Berlin |
| Country | Germany |
| Sector | Private |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Royal Institute of Technology |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Royal Netherlands Academy of Arts and Sciences |
| Department | Hubrecht Institute |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Copenhagen |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Groningen |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Kyoto |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | Centre for Genomic Regulation (CRG) |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | Dando, Weiss & Colucci Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | JDRF Center for Beta Cell Therapy in Diabetes |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | Life and Brain GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | National University of Ireland, Galway |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | University of Milan |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroSyStem |
| Organisation | Austrian Academy of Sciences |
| Department | Institute of Molecular Biotechnology |
| Country | Austria |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | European Institute of Oncology (IEO) |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | German Cancer Research Center |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | Helmholtz Association of German Research Centres |
| Department | Helmholtz Zentrum Munchen |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | Institute of Genetics and Molecular and Cellular Biology (IGBMC) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | Netherlands Cancer Institute (NKI) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | Oxford Gene Technology |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | Pasteur Institute, Paris |
| Country | France |
| Sector | Charity/Non Profit |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | Royal Netherlands Academy of Arts and Sciences |
| Department | Hubrecht Institute |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | San Raffaele Hospital |
| Department | San Raffaele Scientific Institute (SRSI) |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | Swiss Federal Institute of Technology in Lausanne (EPFL) |
| Country | Switzerland |
| Sector | Public |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | Technical University of Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | University Medical Center Gronigen |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | University of Leipzig |
| Department | Ingo Roeder Institute for Medical Informatics |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | University of Milan |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | EuroSyStem |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI and Scientific Coordinator |
| Collaborator Contribution | 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs |
| Impact | see website http://www.eurosystemproject.eu |
| Start Year | 2007 |
| Description | Gene Targeting/ Univ of Edinburgh/ SCI |
| Organisation | University of Edinburgh |
| Department | The Roslin Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Gene targeting by homologous recombination in the rat |
| Collaborator Contribution | Gene targeting by homologous recombination in the rat |
| Impact | n./a |
| Start Year | 2010 |
| Description | George Vassiliou - Cambridge MRC Cancer Unit |
| Organisation | University of Cambridge |
| Department | MRC Cancer Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI George Vassiliou - Collaborative project |
| Collaborator Contribution | Collaboration with Christian Frezza of the University of Cambridge's MRC Cancer Unit entitled "Investigation of metabolic vulnerabilities of clonal haematopoiesis clones." |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | George Vassiliou - David Bates |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: George Vassiliou - academic collaboration |
| Collaborator Contribution | Collaboration with David Bates - academic collaboration. |
| Impact | Academic collaboration |
| Start Year | 2017 |
| Description | George Vassiliou - Gaslini Children's Hospital |
| Organisation | Gaslini Children's Hospital |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | CSCI PI: George Vassiliou; Collaborative research. |
| Collaborator Contribution | Collaboration with Francesco Frassoni; Collaborative research. |
| Impact | Collaborative research. |
| Start Year | 2016 |
| Description | George Vassiliou - John Dick |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CSCI PI: George Vassiliou - academic collaboration. |
| Collaborator Contribution | Collaboration with John Dick - academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2017 |
| Description | George Vassiliou - Kymab Ltd |
| Organisation | Kymab |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: George Vassiliou; Commercial collaboration. |
| Collaborator Contribution | Commercial collaboration. |
| Impact | Commercial collaboration. |
| Start Year | 2016 |
| Description | George Vassiliou - Liran Shlush |
| Organisation | Weizmann Institute of Science |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | CSCI PI: George Vassiliou - academic collaboration. |
| Collaborator Contribution | Collaboration with Liran Shlush - academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2017 |
| Description | George Vassiliou - Memorial Sloane Kettering Cancer Center |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: George Vassiliou; Collaborative research. |
| Collaborator Contribution | Collaboration with Scott Armstrong; Collaborative research. |
| Impact | Collaborative research. |
| Start Year | 2016 |
| Description | George Vassiliou - Sanger |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: George Vassiliou; Collaborative research. |
| Collaborator Contribution | Collaboration with Ele Zeggini, Kosuke Yusa, Paul Kellam; Collaborative research. |
| Impact | Collaborative research. |
| Start Year | 2016 |
| Description | George Vassiliou - Tony Kouzarides |
| Organisation | University of Cambridge |
| Department | Gurdon Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: George Vassiliou - academic collaboration. |
| Collaborator Contribution | Collaboration with Tony Kouzarides - academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2017 |
| Description | Ingo Ringshausen - Acerta |
| Organisation | Acerta |
| Country | Canada |
| Sector | Private |
| PI Contribution | CSCI PI: Ingo Ringshausen; Translational collaboration re testing of BTK inhibitor ACP-196 in pre-clincial CLL models. |
| Collaborator Contribution | Collaboration with Cecile M Krejsa; Translational collaboration re testing of BTK inhibitor ACP-196 in pre-clincial CLL models. |
| Impact | Translational collaboration re testing of BTK inhibitor ACP-196 in pre-clincial CLL models. |
| Start Year | 2016 |
| Description | Ingo Ringshausen - Cecile M. Krejsa |
| Organisation | Acerta |
| Country | Canada |
| Sector | Private |
| PI Contribution | Translational collaboration re testing of BTK inhibitor ACP-196 in pre-clinical CLL models |
| Collaborator Contribution | Translational collaboration re testing of BTK inhibitor ACP-196 in pre-clinical CLL models |
| Impact | None yet |
| Start Year | 2018 |
| Description | JPA/ CSCR |
| Organisation | RIKEN |
| Department | RIKEN Center for Developmental Biology |
| Country | Japan |
| Sector | Public |
| PI Contribution | Metanalysis of transcriptional circuitries and simulation of robustness, flexibility and dynamic heterogeneity |
| Collaborator Contribution | Metanalysis of transcriptional circuitries and simulation of robustness, flexibility and dynamic heterogeneity |
| Impact | n/a |
| Start Year | 2010 |
| Description | Jenny Nichols - Keio University |
| Organisation | Keio University |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Jenny Nichols; Pluripotency in the marmoset. |
| Collaborator Contribution | Collaboration with Erika Sasaki; Pluripotency in the marmoset. |
| Impact | Pluripotency in the marmoset. |
| Start Year | 2013 |
| Description | Jenny Nichols - Memorial Sloane Kettering Cancer Center |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Jenny Nichols; Publication: Le Bin et al., 2014; Early embryonic lineage decision. |
| Collaborator Contribution | Collaboration with Anna Katerina Hadjantonakis; Publication: Le Bin et al., 2014; Early embryonic lineage decision. |
| Impact | Publication: Le Bin et al., 2014; Early embryonic lineage decision. |
| Start Year | 2013 |
| Description | Jenny Nichols - University of Bath |
| Organisation | University of Bath |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Jenny Nichols; Publication: Le Bin et al., 2014; Gene regulatory networks in pluripotent lineages in vivo. |
| Collaborator Contribution | Collaboration with Silvia Munoz-Descalzo; Publication: Le Bin et al., 2014; Gene regulatory networks in pluripotent lineages in vivo. |
| Impact | Publication: Le Bin et al., 2014; Gene regulatory networks in pluripotent lineages in vivo. |
| Start Year | 2013 |
| Description | Jenny Nichols - University of Copenhagen |
| Organisation | University of Copenhagen |
| Department | Danish Stem Cell Center (DanStem) |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Jenny Nichols; Publication: Frankenberg et al., 2014; Morgani et al., 2013. |
| Collaborator Contribution | Collaboration with Joshua Brickman; Publication: Frankenberg et al., 2014; Morgani et al., 2013. |
| Impact | Publication: Frankenberg et al., 2014; Morgani et al., 2013. |
| Start Year | 2009 |
| Description | Jenny Nichols - University of Manchester |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Jenny Nichols; Publication: Grabarek et al., 2012. |
| Collaborator Contribution | Collaboration with Berenika Plusa; Publication: Grabarek et al., 2012. |
| Impact | Publication: Grabarek et al., 2012. |
| Start Year | 2010 |
| Description | Joint research project - Tony Green |
| Organisation | Chinese Academy of Medical Sciences (CAMS) |
| Country | China |
| Sector | Academic/University |
| PI Contribution | CSCI PI, Tony Green - Joint research project |
| Collaborator Contribution | Collaboration with Tao Cheng & Shi Lihong - Joint research project |
| Impact | None yet |
| Start Year | 2019 |
| Description | Joo Hyeon-Lee - Walid Khaled |
| Organisation | University of Cambridge |
| Department | Department of Pharmacology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Joo-Hyeon Lee - Lee lab collaborates with Khaled's group to characterise novel oncogene utilising mouse lung organoid system established in Lee Lab. This work is currently under revision in Nat Com. |
| Collaborator Contribution | Collaboration with Walid Khaled - Lee lab collaborates with Khaled's group to characterise novel oncogene utilising mouse lung organoid system established in Lee Lab. This work is currently under revision in Nat Com. |
| Impact | Lee lab collaborates with Khaled's group to characterise novel oncogene utilising mouse lung organoid system established in Lee Lab. This work is currently under revision in Nat Com. |
| Start Year | 2017 |
| Description | Joo-Hyeon Lee - CIMR |
| Organisation | University of Cambridge |
| Department | Cambridge Institute for Medical Research (CIMR) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Joo-Hyeon Lee; Dr Tammela and myself have been focusing on developing lung cancer models using lung organoid systems. |
| Collaborator Contribution | Collaboration with Tuomas Tammela; Dr Tammela and myself have been focusing on developing lung cancer models using lung organoid systems. |
| Impact | Dr Tammela and myself have been focusing on developing lung cancer models using lung organoid systems. |
| Start Year | 2014 |
| Description | Joo-Hyeon Lee - CIMR (Marciniak) |
| Organisation | University of Cambridge |
| Department | Cambridge Institute for Medical Research (CIMR) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Joo-Hyeon Lee; Lee lab shares our expertise in developing alveolar organoid system, which will be used in establishing a disease model of idiopathic pulmonary fibrosis (IPF) by genetic mutation of Sftpc in Marciniak's group. |
| Collaborator Contribution | Collaboration with Stefan Marciniak; Lee lab shares our expertise in developing alveolar organoid system, which will be used in establishing a disease model of idiopathic pulmonary fibrosis (IPF) by genetic mutation of Sftpc in Marciniak's group. |
| Impact | Lee lab shares our expertise in developing alveolar organoid system, which will be used in establishing a disease model of idiopathic pulmonary fibrosis (IPF) by genetic mutation of Sftpc in Marciniak's group. |
| Start Year | 2016 |
| Description | Joo-Hyeon Lee - Dae-Sik Lim |
| Organisation | Korea Advanced Institute of Science and Technology (KAIST) |
| Country | Korea, Republic of |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Joo-Hyeon Lee - Lee co-supervises Hae-Yon Jeon who is a postdoc in Lim's lab to understand the functional role of Hippo signalling in lung development and regeneration. |
| Collaborator Contribution | Collaboration with Dae-Sik Lim - Lee co-supervises Hae-Yon Jeon who is a postdoc in Lim's lab to understand the functional role of Hippo signalling in lung development and regeneration. |
| Impact | Lee co-supervises Hae-Yon Jeon who is a postdoc in Lim's lab to understand the functional role of Hippo signalling in lung development and regeneration. |
| Start Year | 2017 |
| Description | Joo-Hyeon Lee - Daniel Munoz-Espin |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Lee lab collaborates with Daniel's group to understand the functional role of senescence cells in lung fibrosis and cancer development. Lee lab currently develops novel mouse models to lineage-trace these cells. |
| Collaborator Contribution | Lee lab collaborates with Daniel's group to understand the functional role of senescence cells in lung fibrosis and cancer development. Lee lab currently develops novel mouse models to lineage-trace these cells. |
| Impact | None yet. |
| Start Year | 2018 |
| Description | Joo-Hyeon Lee - Dr Lynne Murray, Prof Maria Belvisi |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Dr Emma Rawlins and Dr Joo-Hyeon Lee submitted MRC-MICA project grant with collaboration of Astrazeneca. |
| Collaborator Contribution | Dr Emma Rawlins and Dr Joo-Hyeon Lee submitted MRC-MICA project grant with collaboration of Astrazeneca. |
| Impact | None yet |
| Start Year | 2018 |
| Description | Joo-Hyeon Lee - Ilaria Malanchi |
| Organisation | Francis Crick Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Lee lab collaborates with Malanchi's group to characterise labelling cells by neighbouring tumour cells utilising mouse lung organoid system established in Lee Lab. This work is currently under revision in Nature. |
| Collaborator Contribution | Lee lab collaborates with Malanchi's group to characterise labelling cells by neighbouring tumour cells utilising mouse lung organoid system established in Lee Lab. This work is currently under revision in Nature. |
| Impact | Publication under revision |
| Start Year | 2018 |
| Description | Joo-Hyeon Lee - Jonghwan Kim |
| Organisation | University of Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Lee lab is actively collaborating with Dr Kim who is an expert in system biology. We try to identify (super)enhancer or TFs for specific lineage specification of lung cell types. |
| Collaborator Contribution | Lee lab is actively collaborating with Dr Kim who is an expert in system biology. We try to identify (super)enhancer or TFs for specific lineage specification of lung cell types. |
| Impact | None yet |
| Start Year | 2018 |
| Description | Joo-Hyeon Lee - Mick Fellow |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Dr Mick co-supervises Kelly Evans who is a PhD student in Lee Lab to establish human lung organoids for use of drug toxicity and CRISPR screening. |
| Collaborator Contribution | Dr Mick co-supervises Kelly Evans who is a PhD student in Lee Lab to establish human lung organoids for use of drug toxicity and CRISPR screening. |
| Impact | None yet |
| Start Year | 2018 |
| Description | Joo-Hyeon Lee - Mick Fellow |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Joo-Hyeon Lee - Dr Mick co-supervises Kelly Evans who is a PhD student in Lee Lab to establish human lung organoids for use of drug toxicity and CRISPR screening. |
| Collaborator Contribution | Collaboration with Mick Fellow - Dr Mick co-supervises Kelly Evans who is a PhD student in Lee Lab to establish human lung organoids for use of drug toxicity and CRISPR screening. |
| Impact | Dr Mick co-supervises Kelly Evans who is a PhD student in Lee Lab to establish human lung organoids for use of drug toxicity and CRISPR screening. |
| Start Year | 2017 |
| Description | Joo-Hyeon Lee - Milner Institute |
| Organisation | University of Cambridge |
| Department | Milner Therapeutics Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Lee lab collaborates with Namshik's group for epigenetic analysis of lung stem cell during lung regeneration and cancer progression. |
| Collaborator Contribution | Lee lab collaborates with Namshik's group for epigenetic analysis of lung stem cell during lung regeneration and cancer progression. |
| Impact | None yet |
| Start Year | 2019 |
| Description | Joo-Hyeon Lee - Papworth Hospital |
| Organisation | Royal Papworth Hospital NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | CSCI PI:: Joo-Hyeon Lee; Lee's group focuses on developing alveolar organoids derived from IPF patient samples. In particular, with Dr Parfrey, we try to understand the crosstalk between epithelial cells, endothelial cells, and fibroblasts in pathogenesis of IPF. |
| Collaborator Contribution | Collaboration with Helen Parfrey; Lee's group focuses on developing alveolar organoids derived from IPF patient samples. In particular, with Dr Parfrey, we try to understand the crosstalk between epithelial cells, endothelial cells, and fibroblasts in pathogenesis of IPF. |
| Impact | Lee's group focuses on developing alveolar organoids derived from IPF patient samples. In particular, with Dr Parfrey, we try to understand the crosstalk between epithelial cells, endothelial cells, and fibroblasts in pathogenesis of IPF. |
| Start Year | 2016 |
| Description | Joo-Hyeon Lee - Papworth Hospital |
| Organisation | Royal Papworth Hospital NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | CSCI PI:: Joo-Hyeon Lee; Lee's group focuses on developing alveolar organoids derived from IPF patient samples. In particular, with Dr Parfrey, we try to understand the crosstalk between epithelial cells, endothelial cells, and fibroblasts in pathogenesis of IPF. |
| Collaborator Contribution | Collaboration with Helen Parfrey; Lee's group focuses on developing alveolar organoids derived from IPF patient samples. In particular, with Dr Parfrey, we try to understand the crosstalk between epithelial cells, endothelial cells, and fibroblasts in pathogenesis of IPF. |
| Impact | Lee's group focuses on developing alveolar organoids derived from IPF patient samples. In particular, with Dr Parfrey, we try to understand the crosstalk between epithelial cells, endothelial cells, and fibroblasts in pathogenesis of IPF. |
| Start Year | 2016 |
| Description | Joo-Hyeon Lee - Sam Janes |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Joo-Hyeon Lee - Lee lab shares our expertise in developing human lung organoid system, which will be used in establishing a modelling human lung cancer with Janes' group. |
| Collaborator Contribution | Collaboration with Sam Janes - Lee lab shares our expertise in developing human lung organoid system, which will be used in establishing a modelling human lung cancer with Janes' group. |
| Impact | Lee lab shares our expertise in developing human lung organoid system, which will be used in establishing a modelling human lung cancer with Janes' group. |
| Start Year | 2017 |
| Description | Joo-Hyeon Lee - Sarah Teichmann |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Lee lab collaborates with Dr Jongeun Park who is a postdoc in Teichmann lab for scRNA-seq analysis. |
| Collaborator Contribution | Lee lab collaborates with Dr Jongeun Park who is a postdoc in Teichmann lab for scRNA-seq analysis. |
| Impact | None yet |
| Start Year | 2018 |
| Description | Joo-Hyeon Lee - University of Cambridge (Enginnering) |
| Organisation | University of Cambridge |
| Department | MRC Biostatistics Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Joo-Hyeon Lee; Huang's group has an expertise in developing biomimetic organ-on-chips for high throughput drug screening. Lee's group is closely collaborating with Dr Huang to recapitulate the microenviroments including a vessel formation for our lung organoids. |
| Collaborator Contribution | Collaboration with Yan Yan Shery Huang; Huang's group has an expertise in developing biomimetic organ-on-chips for high throughput drug screening. Lee's group is closely collaborating with Dr Huang to recapitulate the microenviroments including a vessel formation for our lung organoids. |
| Impact | Huang's group has an expertise in developing biomimetic organ-on-chips for high throughput drug screening. Lee's group is closely collaborating with Dr Huang to recapitulate the microenviroments including a vessel formation for our lung organoids. |
| Start Year | 2016 |
| Description | Joo-Hyeon Lee - University of Cambridge, Department of Biochemistry |
| Organisation | University of Cambridge |
| Department | Department of Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Joo-Hyeon Lee - Collaborative project |
| Collaborator Contribution | Collaboration with Kathryn Lilley of University of Cambridge's Department of Biochemistry. |
| Impact | Outcomes expected 2021 |
| Start Year | 2020 |
| Description | Joo-Hyeon Lee - University of Cambridge, Department of Surgery |
| Organisation | University of Cambridge |
| Department | Department of Surgery |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Joo-Hyeon Lee - Collaborative project |
| Collaborator Contribution | Lee lab collaborates with Dr Kourosh Saeb-Parsy's group for receiving human lung tissue samples to develop patient-derived human lung organoid models. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Joo-Hyeon Lee - Wilhelm Palm and Tuomas Tammela |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Joo-Hyeon Lee - Lee lab shares our expertise in developing lung tumouroids to understand "Metabolic heterogeneity in K-Ras-driven lung cancer" with Palm's lab, Papagiannakoupolos's lab and Tammela's lab. We awarded the Hope Funds Collaborative Competition Award for this collaboration. |
| Collaborator Contribution | Collaboration with Wilhem Palm and Tuomas Tammela - Lee lab shares our expertise in developing lung tumouroids to understand "Metabolic heterogeneity in K-Ras-driven lung cancer" with Palm's lab, Papagiannakoupolos's lab and Tammela's lab. We awarded the Hope Funds Collaborative Competition Award for this collaboration. |
| Impact | Lee lab shares our expertise in developing lung tumouroids to understand "Metabolic heterogeneity in K-Ras-driven lung cancer" with Palm's lab, Papagiannakoupolos's lab and Tammela's lab. We awarded the Hope Funds Collaborative Competition Award for this collaboration. |
| Start Year | 2017 |
| Description | Joo-Hyeon Lee - Young-Suk Ju |
| Organisation | Korea Advanced Institute of Science and Technology (KAIST) |
| Country | Korea, Republic of |
| Sector | Academic/University |
| PI Contribution | Lee lab collaborates with Ju's lab to understand the functional role of Setd2 in alveolar progenitor cells using organoid and mouse system. |
| Collaborator Contribution | Lee lab collaborates with Ju's lab to understand the functional role of Setd2 in alveolar progenitor cells using organoid and mouse system. |
| Impact | None yet. |
| Start Year | 2018 |
| Description | Jose Silva - Black Family Stem Cell Institute |
| Organisation | Mount Sinai Hospital (USA) |
| Department | Black Family Stem Cell Institute |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Jose Silva; Ongoing collaborative work resulting in multiple publications. |
| Collaborator Contribution | Collaboration with Jianlong Wang; Ongoing collaborative work resulting in multiple publications. |
| Impact | Ongoing collaborative work resulting in multiple publications. |
| Start Year | 2011 |
| Description | Kevin Chalut - University of Cambridge (Biochemistry) |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Kevin Chalut; Developing cell encapsulating devices for use with stem cell systems. |
| Collaborator Contribution | Collaboration with Florian Hollfelder; Developing cell encapsulating devices for use with stem cell systems. |
| Impact | Developing cell encapsulating devices for use with stem cell systems. |
| Start Year | 2014 |
| Description | Kevin Chalut - University of Cambridge (Physics) |
| Organisation | University of Cambridge |
| Department | Faculty of Philosophy |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Kevin Chalut; Developed microfluidics for stem cell analysis, recent Nature Materials, coI on submitted BBSRC research grant |
| Collaborator Contribution | Collaboration with Ulrich Keyser; Developed microfluidics for stem cell analysis, recent Nature Materials, coI on submitted BBSRC research grant |
| Impact | Developed microfluidics for stem cell analysis, recent Nature Materials, coI on submitted BBSRC research grant. |
| Start Year | 2012 |
| Description | Kevin Chalut - University of Exeter |
| Organisation | University of Exeter |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Kevin Chalut; Developed microfluidics for stem cell analysis, recent paper in Nature Materials. |
| Collaborator Contribution | Collaboration with Stefano Pagliara; Developed microfluidics for stem cell analysis, recent paper in Nature Materials |
| Impact | Developed microfluidics for stem cell analysis, recent paper in Nature Materials. |
| Start Year | 2011 |
| Description | Kevin Chalut - University of Manchester |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Kevin Chalut; Physical biology of early embryogenesis; collaboration on Leverhulme Trust research grant. |
| Collaborator Contribution | Collaboration with Berenika Plusa; Physical biology of early embryogenesis; collaboration on Leverhulme Trust research grant. |
| Impact | Physical biology of early embryogenesis; collaboration on Leverhulme Trust research grant. |
| Start Year | 2013 |
| Description | Kevin Chalut - Wing Chang |
| Organisation | Stemcell Technologies |
| Country | Canada |
| Sector | Private |
| PI Contribution | Using StemBond hydrogels for human ES cell culture |
| Collaborator Contribution | Using StemBond hydrogels for human ES cell culture |
| Impact | None yet |
| Start Year | 2018 |
| Description | Ludovic Vallier - AstraZeneca |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Ludovic Vallier; Modeling diabetes in vitro using hIPSCs. |
| Collaborator Contribution | Collaboration with Barry Rosen; Modeling diabetes in vitro using hIPSCs. |
| Impact | Modeling diabetes in vitro using hIPSCs. |
| Start Year | 2015 |
| Description | Ludovic Vallier - Babraham Institute |
| Organisation | Babraham Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - collaborative project |
| Collaborator Contribution | Collaboration with Peter Rugg-Gunn - project |
| Impact | Publication |
| Start Year | 2019 |
| Description | Ludovic Vallier - Bit.bio |
| Organisation | Bit.Bio |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Mark Kotter of Bit.bio related to research in forward programming. |
| Impact | Outputs and outcomes expected to begin in 2021 |
| Start Year | 2020 |
| Description | Ludovic Vallier - Boston University |
| Organisation | Boston University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication. |
| Collaborator Contribution | Collaboration with Darrell Kotton; Scientific collaboration; 1 publication. |
| Impact | Scientific collaboration; 1 publication. |
| Start Year | 2013 |
| Description | Ludovic Vallier - CN Bio Innovations Ltd TransTissue Technologies |
| Organisation | CN Bio Innovations Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Ludovic Vallier; Developing 3D system for modeling liver disease. |
| Collaborator Contribution | Collaboration with David Hughes; Developing 3D system for modeling liver disease. |
| Impact | Developing 3D system for modeling liver disease. |
| Start Year | 2010 |
| Description | Ludovic Vallier - California Institute of Technology |
| Organisation | California Institute of Technology |
| Department | Division of Biology and Biological Engineering (BBE) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Magdalena Zernicka-Goetz of Caltech's Division of Biology and Biological Engineering. |
| Impact | Outputs and outcomes expected beginning in 2021 |
| Start Year | 2020 |
| Description | Ludovic Vallier - DefiniGEN |
| Organisation | DefiniGEN |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Ludovic Vallier; Founder and CSO. |
| Collaborator Contribution | Collaboration with Marcus Yeo; CEO |
| Impact | DefiniGEN. |
| Start Year | 2012 |
| Description | Ludovic Vallier - GSK and Ferring |
| Organisation | Ferring Pharmaceuticals |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | CSCI PI Ludovic Vallier - Using genetic screening in a novel in vitro human model of liver disease for target discovery |
| Collaborator Contribution | Using genetic screening in a novel in vitro human model of liver disease for target discovery |
| Impact | None yet |
| Start Year | 2019 |
| Description | Ludovic Vallier - Gauthier Koscielny |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Identification and validation of new target genes for NASH/NAFLD |
| Collaborator Contribution | Identification and validation of new target genes for NASH/NAFLD |
| Impact | None yet |
| Start Year | 2018 |
| Description | Ludovic Vallier - Giuseppe Mazza |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier - collaborative project, grants and publications. |
| Collaborator Contribution | Collaboration with Giuseppe Mazza - collaborative project, grants and publications. |
| Impact | Collaborative project, grants and publications. |
| Start Year | 2017 |
| Description | Ludovic Vallier - Imperial College London |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 2 publications. |
| Collaborator Contribution | Collaboration with Jorge Ferrer; Scientific collaboration; 2 publications. |
| Impact | Scientific collaboration; 2 publications. |
| Start Year | 2010 |
| Description | Ludovic Vallier - Institute of Medical Biology, Singapore |
| Organisation | Agency for Science, Technology and Research (A*STAR) |
| Department | Institute of Medical Biology |
| Country | Singapore |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; publications. |
| Collaborator Contribution | Collaboration with Ray Dunn; Scientific collaboration; publications. |
| Impact | Scientific collaboration; publications. |
| Start Year | 2009 |
| Description | Ludovic Vallier - Jake Liang |
| Organisation | National Institutes of Health (NIH) |
| Country | United States |
| Sector | Public |
| PI Contribution | CSCI PI: Ludovic Valllier - collaborative project, publications. |
| Collaborator Contribution | Collaboration with Jake Liang - collaborative project, publications. |
| Impact | Collaborative project, publications. |
| Start Year | 2017 |
| Description | Ludovic Vallier - Jernej Urle and Kathy Niakkan |
| Organisation | Francis Crick Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier - collaborative project, publications. |
| Collaborator Contribution | Collaboration with Jernej Urle and Kathy Niakan. |
| Impact | Collaborative project, publications. |
| Start Year | 2017 |
| Description | Ludovic Vallier - Kim Jensen |
| Organisation | University of Copenhagen |
| Department | Biotech Research and Innovation Center (BRIC) |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier - Collaborative project, publication. |
| Collaborator Contribution | Collaboration with Kim B Jensen - Collaborative project, publication. |
| Impact | Collaborative project, publication. |
| Start Year | 2017 |
| Description | Ludovic Vallier - Leuven University |
| Organisation | University of Leuven |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - collaborative project |
| Collaborator Contribution | Collaboration with Frederic Lemaigre - project |
| Impact | Publication |
| Start Year | 2019 |
| Description | Ludovic Vallier - Miguel Esteban |
| Organisation | Chinese Academy of Sciences |
| Country | China |
| Sector | Public |
| PI Contribution | Collaborative project, grant and publication |
| Collaborator Contribution | Collaborative project, grant and publication |
| Impact | Grant and publication |
| Start Year | 2018 |
| Description | Ludovic Vallier - Muzz Haniffa |
| Organisation | Newcastle University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaborative project, publication |
| Collaborator Contribution | Collaborative project, publication |
| Impact | Joint publication |
| Start Year | 2018 |
| Description | Ludovic Vallier - NIH |
| Organisation | National Institutes of Health (NIH) |
| Country | United States |
| Sector | Public |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; Publications and grant. |
| Collaborator Contribution | Collaboration with Tom Wynn; Scientific collaboration; Publications and grant. |
| Impact | Scientific collaboration; Publications and grant. |
| Start Year | 2011 |
| Description | Ludovic Vallier - Nancy Papalopulu/Anzy Miller |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaborative project, publication |
| Collaborator Contribution | Collaborative project, publication |
| Impact | Joint publication |
| Start Year | 2018 |
| Description | Ludovic Vallier - Norwegian University of Science and Technology |
| Organisation | Norwegian University of Science and Technology (NTNU) |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Berit Løkensgard Strand - project |
| Impact | Publication |
| Start Year | 2019 |
| Description | Ludovic Vallier - Sanger |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication. |
| Collaborator Contribution | Collaboration with David Gaffney.; Scientific collaboration; 1 publication. |
| Impact | Scientific collaboration; 1 publication. |
| Start Year | 2012 |
| Description | Ludovic Vallier - Sanger |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration. |
| Collaborator Contribution | Collaboration with Oliver Bilker and Gordon Dougan; Scientific collaboration. |
| Impact | Scientific collaboration. |
| Start Year | 2012 |
| Description | Ludovic Vallier - Santi Rodriguez |
| Organisation | University of Buenos Aires |
| Country | Argentina |
| Sector | Academic/University |
| PI Contribution | Collaborative project, grant and publication |
| Collaborator Contribution | Collaborative project, grant and publication |
| Impact | Grant and joint publication |
| Start Year | 2018 |
| Description | Ludovic Vallier - Sarah Teichmann |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Ludovic Vallier - collaborative project, publications. |
| Collaborator Contribution | Collaboration with Sarah Teichman - collaborative project, publications. |
| Impact | Collaborative project, publications. |
| Start Year | 2017 |
| Description | Ludovic Vallier - StemCell Technologies |
| Organisation | Stemcell Technologies |
| Country | Canada |
| Sector | Private |
| PI Contribution | CSCI PI: Ludovic Vallier; Development of culture conditions to differentiate hPSCs into gut organoid. |
| Collaborator Contribution | Collaboration with Michael Riedel; Development of culture conditions to differentiate hPSCs into gut organoid |
| Impact | Development of culture conditions to differentiate hPSCs into gut organoid |
| Start Year | 2015 |
| Description | Ludovic Vallier - Stephen O'Rahilly |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaborative project, publication |
| Collaborator Contribution | Joint publication |
| Impact | Joint publication |
| Start Year | 2018 |
| Description | Ludovic Vallier - Tokyo electron |
| Organisation | Tokyo Electron |
| Country | Japan |
| Sector | Private |
| PI Contribution | CSCI PI: Ludovic Vallier; Development of large scale system for derivation and differentiation of hIPSCs. |
| Collaborator Contribution | Collaboration with Daizo Kurishita; Development of large scale system for derivation and differentiation of hIPSCs. |
| Impact | Development of large scale system for derivation and differentiation of hIPSCs. |
| Start Year | 2012 |
| Description | Ludovic Vallier - Uiversity of Cambridge (Medicine) |
| Organisation | University of Cambridge |
| Department | Department of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 1 grant application. |
| Collaborator Contribution | Collaboration with Andres Floto; Scientific collaboration; 1 grant application. |
| Impact | Scientific collaboration; 1 grant application. |
| Start Year | 2015 |
| Description | Ludovic Vallier - University College London |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 3 publications. |
| Collaborator Contribution | Collaboration with David Lomas; Scientific collaboration; 3 publications. |
| Impact | Scientific collaboration; 3 publications. |
| Start Year | 2010 |
| Description | Ludovic Vallier - University College London |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 3 grant applications. |
| Collaborator Contribution | Collaboration with Paolo De Coppi; Scientific collaboration; 3 grant applications. |
| Impact | Scientific collaboration; 3 grant applications. |
| Start Year | 2012 |
| Description | Ludovic Vallier - University of Bristol |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - collaborative project |
| Collaborator Contribution | Collaboration with Rafael Carazo Salas - project |
| Impact | Publication |
| Start Year | 2019 |
| Description | Ludovic Vallier - University of California at Davis |
| Organisation | University of California, Davis |
| Department | UC Davis College of Biological Sciences |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Gerald Quon of UC-Davis College of Biological Sciences |
| Impact | Outputs and outcomes expected beginning 2021 |
| Start Year | 2020 |
| Description | Ludovic Vallier - University of Cambridge (Haematology) |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration. |
| Collaborator Contribution | Collaboration with Cedric Ghevaert and Willem Ouwehand; scientific collaboration. |
| Impact | Scientific collaboration. |
| Start Year | 2012 |
| Description | Ludovic Vallier - University of Cambridge (Medicine - Lehner) |
| Organisation | University of Cambridge |
| Department | Department of Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication. |
| Collaborator Contribution | Collaboration with Paul Lehner; Scientific collaboration; 1 publication. |
| Impact | Scientific collaboration; 1 publication. |
| Start Year | 2015 |
| Description | Ludovic Vallier - University of Cambridge (Spillantini) |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration. |
| Collaborator Contribution | Collaboration with Maria Grazia Spillantini; Scientific collaboration. |
| Impact | Scientific collaboration. |
| Start Year | 2012 |
| Description | Ludovic Vallier - University of Cambridge (Surgery/Medicine) |
| Organisation | University of Cambridge |
| Department | Department of Public Health and Primary Care |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; grant application. |
| Collaborator Contribution | Collaboration with Kourosh Saeb-Parsy; Scientific collaboration; grant application. |
| Impact | Scientific collaboration; grant application. |
| Start Year | 2013 |
| Description | Ludovic Vallier - University of Cambridge (Vidal-Puig) |
| Organisation | University of Cambridge |
| Department | Department of Haematology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration. |
| Collaborator Contribution | Collaboration with Toni Vidal-Puig; Scientific collaboration. |
| Impact | Scientific collaboration. |
| Start Year | 2015 |
| Description | Ludovic Vallier - University of Edinburgh |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication and grant application. |
| Collaborator Contribution | Collaboration with Siddharthan Chandran; Scientific collaboration; 1 publication and grant application. |
| Impact | Scientific collaboration; 1 publication and grant application. |
| Description | Ludovic Vallier - University of Exeter |
| Organisation | University of Exeter |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication. |
| Collaborator Contribution | Collaboration with Andrew Hatersley; Scientific collaboration; 1 publication. |
| Impact | Scientific collaboration; 1 publication. |
| Start Year | 2010 |
| Description | Ludovic Vallier - University of Georgia |
| Organisation | University of Georgia |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication. |
| Collaborator Contribution | Collaboration with Stephen Dalton; Scientific collaboration; 1 publication. |
| Impact | Scientific collaboration; 1 publication. |
| Start Year | 2012 |
| Description | Ludovic Vallier - University of Manchester |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ludovic Vallier; Scientific collaboration; 3 publications. |
| Collaborator Contribution | Collaboration with Neil Hanley; Scientific collaboration; 3 publications. |
| Impact | Scientific collaboration; 3 publications. |
| Start Year | 2010 |
| Description | Ludovic Vallier - University of Oxford |
| Organisation | University of Oxford |
| Department | Department of Physiology, Anatomy and Genetics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Shankar Srinivas of Oxford's Department of Physiology, Anatomy and Genetics. |
| Impact | Outputs and outcomes beginning in 2021 |
| Start Year | 2020 |
| Description | Ludovic Vallier - University of Washington |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Kelly Stevens of the University of Washington's College of Engineering |
| Impact | Outputs and outcomes beginning in 2021 |
| Start Year | 2020 |
| Description | Maria Alcolea - Alessandro Esposito |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Cancer Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Maria Alcolea. Research collaboration. |
| Collaborator Contribution | Collaboration with Alessandro Esposito; Research Collaboration. |
| Impact | Research collaboration - ongoing. |
| Start Year | 2017 |
| Description | Maria Alcolea - Antonia Obrador |
| Organisation | Hospital Son Espases |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Maria Alcolea. Research collaboration |
| Collaborator Contribution | Collaboration with Antonia Obrador; Research collaboration |
| Impact | Research collaboration - ongoing |
| Start Year | 2017 |
| Description | Maria Alcolea - Ben Simons |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Maria Alcolea. PhD student and postdoc co-supervision; MRC research grant collaboration. |
| Collaborator Contribution | Collaboration with Ben Simons; PhD student and postdoc co-supervision; MRC research grant collaboration. |
| Impact | PhD student and postdoc co-supervision; MRC research grant collaboration. |
| Start Year | 2016 |
| Description | Maria Alcolea - Daniel Munoz-Espin |
| Organisation | University of Cambridge |
| Department | Department of Oncology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Maria Alcolea. Research collaboration. |
| Collaborator Contribution | Collaboration with Daniel Munoz-Espin; Research collaboration |
| Impact | Research collaboration - ongoing |
| Start Year | 2017 |
| Description | Maria Alcolea - George Gordon/ Sarah Bondiek |
| Organisation | Cancer Research UK Cambridge Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Maria Alcolea; Research collaboration |
| Collaborator Contribution | Collaboration with George Gordon/ Sarah Bondiek; Research collaboration |
| Impact | Research collaboration |
| Start Year | 2016 |
| Description | Maria Alcolea - Julio Saez-Rodriguez |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Maria Alcolea. Research collaboration. |
| Collaborator Contribution | Collaboration with Julio Saez-Rodriguez; Research collaboration. |
| Impact | Research collaboration - ongoing. |
| Start Year | 2017 |
| Description | Maria Alcolea - Pedro Cutillas |
| Organisation | Queen Mary University of London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Research collaboration |
| Collaborator Contribution | Research collaboration |
| Impact | None yet |
| Start Year | 2018 |
| Description | Methylation analyses |
| Organisation | Babraham Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Methylation analyses |
| Collaborator Contribution | Methylation analyses |
| Impact | n/a |
| Start Year | 2011 |
| Description | NeuroStemCell |
| Organisation | Babraham Institute |
| Department | Stem Cell Sciences UK Ltd |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | Cardiff University |
| Department | School of Biosciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | Institute of Biomedical Imagery (I2BM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | NsGene A/S |
| Country | Denmark |
| Sector | Private |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | Sapio |
| Department | BioRep |
| Country | Italy |
| Sector | Private |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | University of Bonn |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | NeuroStemCell |
| Organisation | University of Milan |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells. |
| Collaborator Contribution | European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models. |
| Impact | http://www.neurostemcell.org/ |
| Start Year | 2008 |
| Description | Pluripotency in marmoset |
| Organisation | Central Institute for Experimental Animals (CIEA) |
| Country | Japan |
| Sector | Private |
| PI Contribution | Pluripotency in marmoset |
| Collaborator Contribution | Pluripotency in marmoset |
| Impact | None yet |
| Start Year | 2019 |
| Description | Research Collaboration |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ana Cvejic, Research collaboration |
| Collaborator Contribution | Collaboration with Judith Zaugg |
| Impact | None yet |
| Start Year | 2019 |
| Description | Robin Franklin - Daniel Bradley, Dr Hui-Hsin Tsai |
| Organisation | Biogen |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Joint grant |
| Collaborator Contribution | Joint grant |
| Impact | none yet |
| Start Year | 2018 |
| Description | Robin Franklin - Domainex |
| Organisation | Domainex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Robin Franklin; Drug development. |
| Collaborator Contribution | Collaboration with George Buckley; Drug development |
| Impact | Drug development. |
| Start Year | 2016 |
| Description | Robin Franklin - GSK |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: Robin Franklin; Case Studentship. |
| Collaborator Contribution | Collaboration with Gareth Wayne; Case Studentship. |
| Impact | Case Studentship. |
| Start Year | 2014 |
| Description | Robin Franklin - INSERM |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Robin Franklin; Single publication. |
| Collaborator Contribution | Collaboration with Catherine Lubetzki; Single publication. |
| Impact | Single publication. |
| Start Year | 2010 |
| Description | Robin Franklin - Lynette Foo |
| Organisation | Roche Pharmaceuticals |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: Robin Franklin; Joint grant. |
| Collaborator Contribution | Collaboration with Lynette Foo - joint grant |
| Impact | Joint grant. |
| Start Year | 2017 |
| Description | Robin Franklin - MedImmune |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Robin Franklin; Project grant and Studentship. |
| Collaborator Contribution | Collaboration with Clare Jones; Project grant and Studentship. |
| Impact | Project grant and Studentship. |
| Start Year | 2014 |
| Description | Robin Franklin - Mount Sinai Hospital |
| Organisation | Mount Sinai Hospital (USA) |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Robin Franklin; Single publication. |
| Collaborator Contribution | Collaboration with Patrizia Casaccia; Single publication |
| Impact | Single publication. |
| Start Year | 2010 |
| Description | Robin Franklin - University of California San Francisco |
| Organisation | University of California, San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Robin Franklin; Joint publications. |
| Collaborator Contribution | Collaboration with Jonah Chan; Joint publications. |
| Impact | Joint publications. |
| Start Year | 2012 |
| Description | Robin Franklin - University of Cambridge (Clinical Neurosciences) |
| Organisation | University of Cambridge |
| Department | Department of Genetics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Robin Franklin; Joint grants and publications. |
| Collaborator Contribution | Collaboration with Mark Kotter. Joint grants and publications. |
| Impact | Joint grants and publications. |
| Description | Robin Franklin - University of Edinburgh |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Robin Franklin. |
| Collaborator Contribution | Collaboration with David Lyons. |
| Impact | None yet. |
| Start Year | 2012 |
| Description | Robin Franklin - University of Edinburgh |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Robin Franklin; Several publications and grants. |
| Collaborator Contribution | Collaboration with Charles ffrench-Constant; Several publications and grants. |
| Impact | Several publications and grants. |
| Description | Roger Barker - Andreas Bosio |
| Organisation | Miltenyi Biotec GmBH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Improved imaging of human postmortem brain tissue |
| Collaborator Contribution | Improved imaging of human postmortem brain tissue |
| Impact | None yet |
| Start Year | 2018 |
| Description | Roger Barker - Cell Therapy Catapult |
| Organisation | Cell Therapy Catapult |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Roger Barker - Discussion on ES cell trials in PD |
| Collaborator Contribution | Collaboration with Nina Bauer - Discussion on ES cell trials in PD |
| Impact | Discussion on ES cell trials in PD. |
| Start Year | 2015 |
| Description | Roger Barker - Karolinska Institute |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | SCI PI: Roger Bartker; EU FP7 grant DDPD genes - Defining genes involved in dopamine differentiation and loss in PD |
| Collaborator Contribution | Collaboration with Ernest Arenas - EU FP7 grant DDPD genes - Defining genes involved in dopamine differentiation and loss in PD |
| Impact | EU FP7 grant DDPD genes - Defining genes involved in dopamine differentiation and loss in PD. |
| Start Year | 2011 |
| Description | Roger Barker - Lund University |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Roger Barker - Disease modelling with iN cells |
| Collaborator Contribution | Collaboration with Malin Parmar - Disease modelling with iN cells |
| Impact | Disease modelling with iN cells. |
| Start Year | 2011 |
| Description | Roger Barker - Lund University |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CSCI PI Roger Barker - Collaborative Project |
| Collaborator Contribution | Collaboration with Johan Jakobsson titled "Role of transposons in driving inflammation in Parkinson's Disease". |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Roger Barker - Lund University (Bjorklund) |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Roger Barker; Neural grafting in PD and disease modelling in PD. |
| Collaborator Contribution | Collaboration with Anders Bjorklund - Neural grafting in PD and disease modelling in PD |
| Impact | Neural grafting in PD and disease modelling in PD. |
| Start Year | 2011 |
| Description | Roger Barker - MRC Centre for Regenerative Medicine |
| Organisation | University of Edinburgh |
| Department | MRC Centre for Regenerative Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | SCI PI: Roger Barker; MRC grant to make GMP grade dopamine cells from hES cells |
| Collaborator Contribution | Collaboration with Tilo Kunath; MRC grant to make GMP grade dopamine cells from hES cells |
| Impact | MRC grant to make GMP grade dopamine cells from hES cells. |
| Start Year | 2012 |
| Description | Roger Barker - MedImmune |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Roger Barker - Project around patient samples and stem cell line from patients |
| Collaborator Contribution | Collaboration with Andy Billington - Project around patient samples and stem cell line from patients |
| Impact | Project around patient samples and stem cell line from patients. |
| Start Year | 2015 |
| Description | Roger Barker - Miltenyi |
| Organisation | Miltenyi Biotec GmBH |
| Country | Germany |
| Sector | Private |
| PI Contribution | iPSC dopaminergic neurons for use in Parkinson's disease |
| Collaborator Contribution | iPSC dopaminergic neurons for use in Parkinson's disease |
| Impact | None yet |
| Start Year | 2019 |
| Description | Roger Barker - Novo Nordisk - Cambridge Design Partnership |
| Organisation | Cambridge Design Partnership |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI Roger Barker - Collaborative project |
| Collaborator Contribution | Collaboration between Roger Barker, Novo Nordisk and the Cambridge Design Partnership to develop dopaminergic stem cells for the treatment of Parkinson's Disease. |
| Impact | Outputs and outcomes beginning in 2021. |
| Start Year | 2020 |
| Description | Roger Barker - Novo Nordisk - Cambridge Design Partnership |
| Organisation | Novo Nordisk |
| Country | Denmark |
| Sector | Private |
| PI Contribution | CSCI PI Roger Barker - Collaborative project |
| Collaborator Contribution | Collaboration between Roger Barker, Novo Nordisk and the Cambridge Design Partnership to develop dopaminergic stem cells for the treatment of Parkinson's Disease. |
| Impact | Outputs and outcomes beginning in 2021. |
| Start Year | 2020 |
| Description | Roger Barker - Pedro R. Cutillas |
| Organisation | Queen Mary University of London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Roger Barker; Research collaboration. |
| Collaborator Contribution | Collaboration with Pedro R. Cutillas - research collaboration. |
| Impact | Research collaboration - ongoing |
| Start Year | 2017 |
| Description | Roger Barker - Pluripotent Stem Cell Plataform (Sheffield) |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Roger Barker - Genetic/Epigenetic abnormalities in ES derived neurons and induced neurons |
| Collaborator Contribution | Collaboration with Peter Andrews - Genetic/Epigenetic abnormalities in ES derived neurons and induced neurons |
| Impact | Genetic/Epigenetic abnormalities in ES derived neurons and induced neurons. |
| Start Year | 2013 |
| Description | Roger Barker - Pluripotent Stem Cell Platform (PSCP) |
| Organisation | Loughborough University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Roger Barker - GMP production of hES cells to dopamine neurons |
| Collaborator Contribution | Collaboration with Mark McCall - GMP production of hES cells to dopamine neurons |
| Impact | GMP production of hES cells to dopamine neurons. |
| Start Year | 2014 |
| Description | Roger Barker - Sarah Teichmann |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Single cell atlas of developing human fetus |
| Collaborator Contribution | Single cell atlas of developing human fetus |
| Impact | None yet |
| Start Year | 2018 |
| Description | Roger Barker - University of Milan |
| Organisation | University of Milan |
| Department | Stem Cell Biology and Pharmacology of Neurodegenerative Diseases |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Roger Barker; Striatial development in the human and the making of MSNs from hES cells |
| Collaborator Contribution | Collaboration with Elena Cattaneo - Striatial development in the human and the making of MSNs from hES cells |
| Impact | Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases. |
| Start Year | 2008 |
| Description | Sanjay Sinha - AstraZeneca |
| Organisation | AstraZeneca |
| Department | AstraZeneca Sweden |
| Country | Sweden |
| Sector | Private |
| PI Contribution | CSCI PI Sanjay Sinha - Collaborative project |
| Collaborator Contribution | Collaborative research with Ryan Hicks of AstraZeneca Sweden. |
| Impact | Outputs and outcomes beginning in 2021 |
| Start Year | 2020 |
| Description | Sanjay Sinha - Hemoshear Therapeutics |
| Organisation | Hemoshear Therapeutics |
| Country | United States |
| Sector | Private |
| PI Contribution | CSCI PI: Sanjay Sinha; Joint paper submitted. |
| Collaborator Contribution | Collaboration with Brian Wamhoff; Joint paper submitted. |
| Impact | Joint paper submitted. |
| Start Year | 2015 |
| Description | Sanjay Sinha - INSERM |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Department | Inserm Transfert |
| Country | France |
| Sector | Public |
| PI Contribution | CSCI PI: Sanjay Sinha; Stroke Association grant. |
| Collaborator Contribution | Collaboration with Anne Joutel; Stroke Association grant. |
| Impact | Stroke Association grant. |
| Start Year | 2015 |
| Description | Sanjay Sinha - Imperial College London |
| Organisation | Imperial College London |
| Department | Department of Bioengineering |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Sanjay Sinha - Joint Grant awarded by Kusuma Trust |
| Collaborator Contribution | The Kusuma Trust awarded a grant to Dr Sanjay Sinha (Wellcome - MRC Cambridge Stem Cell Institute) and Prof Molly Stevens (Imperial College London) to work together on developing an innovative material strategy to heal the heart. This follows on from some initial successful research carried out by the Stevens Group to develop cardiac patches. This next phase of research will use the expertise of both groups in cardiac cell biology and biomaterials to develop pioneering new materials. If successful, this therapeutic approach will strengthen and support heart regeneration and is potentially a highly promising solution for the treatment of heart failure. We look forward to seeing the outcome of this research and the impact that it could have. |
| Impact | Outcomes expected beginning 2021 |
| Start Year | 2020 |
| Description | Sanjay Sinha - Leiden University Medical Centre |
| Organisation | Leiden University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Sanjay Sinha; Collaborative research. |
| Collaborator Contribution | Collaboration with Annemieke Aartma-Rus; Collaborative research. |
| Impact | Collaborative research. |
| Start Year | 2015 |
| Description | Sanjay Sinha - University of Cambridge |
| Organisation | University of Cambridge |
| Department | Department of Chemical Engineering and Biotechnology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Sanjay Sinha; Collaborative research. |
| Collaborator Contribution | Collaboration with Ziad Mallat; Collaborative research. |
| Impact | Collaborative research. |
| Start Year | 2014 |
| Description | Sanjay Sinha - University of Cambridge (Chris Smith) |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Sanjay Sinha; Joint grat (BHF) |
| Collaborator Contribution | Collaboration with Chris Smith; Joint grant (BHF). |
| Impact | Joint grant (BHF). |
| Start Year | 2016 |
| Description | Sanjay Sinha - University of Cambridge (Farndale) |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Sanjay Sinha; Joint grant (BHF) |
| Collaborator Contribution | Collaboration with Richard Farndale; Joint grant (BHF). |
| Impact | Joint grant (BHF) |
| Start Year | 2012 |
| Description | Sanjay Sinha - University of Oxford |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Sanjay Sinha; Collaborative research. |
| Collaborator Contribution | Collaboration with Paul Riley and Shoumo Bhattachariya; Collaborative research. |
| Impact | Collaborative research. |
| Start Year | 2013 |
| Description | Sanjay Sinha - University of Washington |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Sanjay Sinha; BHF grant |
| Collaborator Contribution | Collaboration with Chuck Murry; BHF grant. |
| Impact | BHF grant. |
| Start Year | 2014 |
| Description | Sanjay Sinha - Yale University |
| Organisation | Yale University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Sanjay Sinha; Collaborative research. |
| Collaborator Contribution | Collaboration with Laura Niklason; Collaborative research. |
| Impact | Collaborative research. |
| Start Year | 2012 |
| Description | Simon Buczacki - Mike Stratton |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Sharing of primary intestinal tissue |
| Collaborator Contribution | Sharing of primary intestinal tissue |
| Impact | None yet. |
| Start Year | 2018 |
| Description | Simon Mendez-Ferrer - Basel University Hospital |
| Organisation | University Hospital Basel |
| Country | Switzerland |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Simon Mendez-Ferrer; This group has provided a mouse model of MLL-AF9 acute myeloid leukemia and bone marrow biopsies from AML patients. |
| Collaborator Contribution | Collaboration with Juerg Schwaller; This group has provided a mouse model of MLL-AF9 acute myeloid leukemia and bone marrow biopsies from AML patients. |
| Impact | This group has provided a mouse model of MLL-AF9 acute myeloid leukemia and bone marrow biopsies from AML patients. |
| Start Year | 2012 |
| Description | Simon Mendez-Ferrer - Basel University Hospital (Skoda) |
| Organisation | University Hospital Basel |
| Country | Switzerland |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Simon Mendez-Ferrer; We have obtained from this group mouse models of myeloproliferative neoplasms, murine and human samples carrying these mutations. |
| Collaborator Contribution | Collaboration with Radek Skoda; We have obtained from this group mouse models of myeloproliferative neoplasms, murine and human samples carrying these mutations. |
| Impact | We have obtained from this group mouse models of myeloproliferative neoplasms, murine and human samples carrying these mutations. |
| Start Year | 2012 |
| Description | Simon Mendez-Ferrer - British Council |
| Organisation | British Council |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Simon Mendez-Ferrer; Shortlisted co-application to the Birtish Council BIRAX Program with Prof. Tsvee Lapidot, Weizmann Institute, Israel. |
| Collaborator Contribution | Collaboration with Julia Schwartz; Shortlisted co-application to the Birtish Council BIRAX Program with Prof. Tsvee Lapidot, Weizmann Institute, Israel. |
| Impact | Shortlisted co-application to the Birtish Council BIRAX Program with Prof. Tsvee Lapidot, Weizmann Institute, Israel. |
| Start Year | 2016 |
| Description | Simon Mendez-Ferrer - CNIC |
| Organisation | Spanish National Centre for Cardiovascular Research |
| Country | Spain |
| Sector | Public |
| PI Contribution | CSCI PI: Simon Mendez-Ferrer; High-throughput mass spectrometry analyses. |
| Collaborator Contribution | Collaboration with Jesus Vazquez; High-throughput mass spectrometry analyses. |
| Impact | High-throughput mass spectrometry analyses. |
| Start Year | 2012 |
| Description | Simon Mendez-Ferrer - Galvani Bioelectronics |
| Organisation | Galvani Bioelectronics Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Simon Mendez-Ferrer; Collaboration agreement with Galvani Bioelectronics, a joint venture of GSK and Google LifeScience. |
| Collaborator Contribution | Collaboration with Alessandra Giarola; Collaboration agreement with Galvani Bioelectronics, a joint venture of GSK and Google LifeScience. |
| Impact | Collaboration agreement with Galvani Bioelectronics, a joint venture of GSK and Google LifeScience. |
| Start Year | 2016 |
| Description | Simon Mendez-Ferrer - Ichan School of Medicine |
| Organisation | Icahn School of Medicine at Mount Sinai |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Simon Mendez-Ferrer; This group performed bone analyses of mice where nestin+ cells had been genetically depleted. |
| Collaborator Contribution | Collaboration with Mon Zaidi; This group performed bone analyses of mice where nestin+ cells had been genetically depleted. |
| Impact | This group performed bone analyses of mice where nestin+ cells had been genetically depleted. |
| Start Year | 2010 |
| Description | Simon Mendez-Ferrer - University of Cambridge |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Simon Mendez-Ferrer; Transmission Electron Microscopy. |
| Collaborator Contribution | Collaboration with Jeremy Skepper; Transmission Electron Microscopy. |
| Impact | Transmission Electron Microscopy. |
| Start Year | 2016 |
| Description | Simon Mendez-Ferrer - University of Helsinki |
| Organisation | University of Helsinki |
| Country | Finland |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Simon Mendez-Ferrer; Provided Gfra2 KO mice. |
| Collaborator Contribution | Collaboration with Matti S Airaksinen; Provided Gfra2 KO mice. |
| Impact | Provided Gfra2 KO mice. |
| Start Year | 2010 |
| Description | Simon Mendez-Ferrer - University of Wurzburg |
| Organisation | Medical University of Wurzburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Simon Mendez-Ferrer; Provided samples from CNTF KO mice. |
| Collaborator Contribution | Collaboration with Michael Stendtner; Provided samples from CNTF KO mice. |
| Impact | Provided samples from CNTF KO mice. |
| Start Year | 2016 |
| Description | Sinergia |
| Organisation | Friedrich Miescher Institute for Biomedical Research (FMI) |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Analysis of self-renewal mechanism in pluripotent stem cells, in particular the role of leukaemia inhibitory factor. |
| Collaborator Contribution | Analysis of self-renewal mechanism in pluripotent stem cells, in particular the role of leukaemia inhibitory factor. |
| Impact | none - this is not multidisciplinary |
| Start Year | 2010 |
| Description | Sinergia |
| Organisation | University of Basel |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Analysis of self-renewal mechanism in pluripotent stem cells, in particular the role of leukaemia inhibitory factor. |
| Collaborator Contribution | Analysis of self-renewal mechanism in pluripotent stem cells, in particular the role of leukaemia inhibitory factor. |
| Impact | none - this is not multidisciplinary |
| Start Year | 2010 |
| Description | Sinergia |
| Organisation | University of Zurich |
| Department | Institute of Anatomy |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Analysis of self-renewal mechanism in pluripotent stem cells, in particular the role of leukaemia inhibitory factor. |
| Collaborator Contribution | Analysis of self-renewal mechanism in pluripotent stem cells, in particular the role of leukaemia inhibitory factor. |
| Impact | none - this is not multidisciplinary |
| Start Year | 2010 |
| Description | Single cell studies (malaria); Joint grant application. |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Bertie Gottgens, Single cell studies (malaria); Joint grant application. |
| Collaborator Contribution | Collaboration with Cristina Lo Celso, Single cell studies (malaria); Joint grant application. |
| Impact | None yet |
| Start Year | 2019 |
| Description | Sion Mendez-Ferrer - Imperial College London |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Simon Mendez-Ferrer; Intravital microscopy. |
| Collaborator Contribution | Collaboration with Cristina Lo Celso; Intravital microscopy. |
| Impact | Intravital microscopy. |
| Start Year | 2016 |
| Description | Small molecular inhibitors of NuRD function - Brian Hendrich |
| Organisation | Max Planck Society |
| Department | Max Planck Institute for Molecular Physiology |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - Small molecular inhibitors of NuRD function |
| Collaborator Contribution | Collaboration with Peter t-Hart - Small molecular inhibitors of NuRD function |
| Impact | None yet |
| Start Year | 2019 |
| Description | Srinjan Basu - David Holcman |
| Organisation | École Normale Supérieure, Paris |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Working on collaborative project to develop single-molecule imaging algorithms |
| Collaborator Contribution | Working on collaborative project to develop single-molecule imaging algorithms |
| Impact | None yet. |
| Start Year | 2018 |
| Description | Srinjan Basu - David Klenerman |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Working on collaborative project to develop single-molecule imaging methods |
| Collaborator Contribution | Working on collaborative project to develop single-molecule imaging methods |
| Impact | None yet. |
| Start Year | 2018 |
| Description | Srinjan Basu - Ernest Laue |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Working on collaborative project to study NuRD complex using single-molecule imaging |
| Collaborator Contribution | Working on collaborative project to study NuRD complex using single-molecule imaging |
| Impact | Publication |
| Start Year | 2018 |
| Description | Srinjan Basu - Thorsten Boroviak |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-supervised Master's student to develop embryo imaging |
| Collaborator Contribution | Co-supervised Master's student to develop embryo imaging |
| Impact | Co-supervised Master's student to develop embryo imaging. |
| Start Year | 2018 |
| Description | Stefano Pluchino - Cell Therapy Catapult |
| Organisation | Cell Therapy Catapult |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Stefano Pluchino; Discussion of potential R&D activities in preparation to a phase I clinical trial with patient-specific induced NSCs. |
| Collaborator Contribution | Collaboration with Charlotte Milnes and Jacqueline Barry; Discussion of potential R&D activities in preparation to a phase I clinical trial with patient-specific induced NSCs. |
| Impact | Discussion of potential R&D activities in preparation to a phase I clinical trial with patient-specific induced NSCs. |
| Start Year | 2015 |
| Description | Stefano Pluchino - EBI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint papers, grants and student supervisions. |
| Collaborator Contribution | Collaboration with Anton Enright; Joint papers, grants and student supervisions. |
| Impact | Joint papers, grants and student supervisions. |
| Start Year | 2011 |
| Description | Stefano Pluchino - IRCCS |
| Organisation | IRCCS Oasi Maria SS |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint grants and publications. |
| Collaborator Contribution | Collaboration with Bianca Marchetti; Joint grants and publications. |
| Impact | Joint grants and publications. |
| Start Year | 2007 |
| Description | Stefano Pluchino - MRC Mitochondrial Biology Unit |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Mitochondrial Biology Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint projects. |
| Collaborator Contribution | Collaboration with Mike Murphy; Joint projects. |
| Impact | Joint projects. |
| Start Year | 2016 |
| Description | Stefano Pluchino - NIH/NINDS |
| Organisation | National Institutes of Health (NIH) |
| Department | National Institute of Neurological Disorders and Stroke (NINDS) |
| Country | United States |
| Sector | Public |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint PhD students supervisions. |
| Collaborator Contribution | Collaboration with John Hallenbeck; Joint PhD students supervisions. |
| Impact | Joint PhD students supervisions. |
| Start Year | 2013 |
| Description | Stefano Pluchino - Tohoku University |
| Organisation | Tohoku University |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino;Joint grants and student supervision. |
| Collaborator Contribution | Collaboration with Mari Dezawa; Joint grants and student supervision. |
| Impact | Joint grants and student supervision. |
| Start Year | 2014 |
| Description | Stefano Pluchino - Uniformed Services University of Health Sciences |
| Organisation | Uniformed Services University of the Health Services |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint grants. |
| Collaborator Contribution | Collaboration with Regina Armstrong; Joint grants. |
| Impact | Joint grants. |
| Start Year | 2014 |
| Description | Stefano Pluchino - University Hospital Zurich |
| Organisation | University Hospital Zürich |
| Country | Switzerland |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint publications. |
| Collaborator Contribution | Collaboration with Dirk Hermann; Joint publications. |
| Impact | Joint publications. |
| Start Year | 2006 |
| Description | Stefano Pluchino - University of Cambridge (MRC Cancer Unit) |
| Organisation | University of Cambridge |
| Department | MRC Cancer Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint grants and student supervision. |
| Collaborator Contribution | Collaboration with Christian Frezza; Joint grants and student supervision. |
| Impact | Joint grants and student supervision. |
| Start Year | 2013 |
| Description | Stefano Pluchino - University of Kentucky |
| Organisation | University of Kentucky |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint projects and grants. |
| Collaborator Contribution | Collaboration with Peixuan Guo; Joint projects and grants. |
| Impact | Joint projects and grants. |
| Start Year | 2012 |
| Description | Stefano Pluchino - University of Queensland |
| Organisation | University of Queensland |
| Department | Institute for Molecular Bioscience |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint grants and publications. |
| Collaborator Contribution | Collaboration with John S. Mattick; Joint grants and publications. |
| Impact | Joint grants and publications. |
| Start Year | 2010 |
| Description | Stefano Pluchino - University of Salento |
| Organisation | University of Salento |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint grants and publications. |
| Collaborator Contribution | Collaboration with Pasquina Marzola; Joint grants and publications. |
| Impact | Joint grants and publications. |
| Start Year | 2007 |
| Description | Stefano Pluchino - University of Valencia |
| Organisation | University of Valencia |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint grants and publications. |
| Collaborator Contribution | Collaboration with Jose-Manuel Garcia-Verdugo; Joint grants and publications. |
| Impact | Joint grants and publications. |
| Description | Stefano Pluchino - University of Vermont |
| Organisation | University of Vermont |
| Department | Department of Neurology |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint grant applications. |
| Collaborator Contribution | Collaboration with Yang Mao-Draayer; Joint grant applications. |
| Impact | Joint grant applications. |
| Start Year | 2008 |
| Description | Stefano Pluchino - University of Wurzburg |
| Organisation | Medical University of Wurzburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Stefano Pluchino; Joint grants and student supervisions. |
| Collaborator Contribution | Collaboration with Frank Edenhofer; Joint grants and student supervisions. |
| Impact | Joint grants and student supervisions. |
| Start Year | 2013 |
| Description | SyBoSS |
| Organisation | Claudius Regaud Hospital |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration |
| Collaborator Contribution | Biologists, chemists, physicists and bioinformaticians from five European countries have been engaged by the EU Seventh Framework to work out how stem cells differentiate. How a simple stem cell becomes a highly specialized member of a network, and how those conditions could be recreated in treating disease, is the focus of the Systems Biology of Stem Cells and Reprogramming project. When most human tissues are damaged, the wound is healed by cell division, to grow back skin, muscle or bone. On injury, the injured part is temporarily returned to a less specialized state. Once the signals to keep dividing are gone, the new cells establish different molecular interactions that give them their special functions. Adult nerve cells were previously not thought to regenerate. However, we now know that even in the adult human brain, new nerve cells arise. Exercise, enriched environment, good nutrition, sunlight, and fresh air all help to regenerate nerve cells. Exactly how this happens, is what the SyBoSS research initiative intends to find out. |
| Impact | not currently known |
| Start Year | 2010 |
| Description | SyBoSS |
| Organisation | Erasmus MC |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration |
| Collaborator Contribution | Biologists, chemists, physicists and bioinformaticians from five European countries have been engaged by the EU Seventh Framework to work out how stem cells differentiate. How a simple stem cell becomes a highly specialized member of a network, and how those conditions could be recreated in treating disease, is the focus of the Systems Biology of Stem Cells and Reprogramming project. When most human tissues are damaged, the wound is healed by cell division, to grow back skin, muscle or bone. On injury, the injured part is temporarily returned to a less specialized state. Once the signals to keep dividing are gone, the new cells establish different molecular interactions that give them their special functions. Adult nerve cells were previously not thought to regenerate. However, we now know that even in the adult human brain, new nerve cells arise. Exercise, enriched environment, good nutrition, sunlight, and fresh air all help to regenerate nerve cells. Exactly how this happens, is what the SyBoSS research initiative intends to find out. |
| Impact | not currently known |
| Start Year | 2010 |
| Description | SyBoSS |
| Organisation | European Molecular Biology Laboratory |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration |
| Collaborator Contribution | Biologists, chemists, physicists and bioinformaticians from five European countries have been engaged by the EU Seventh Framework to work out how stem cells differentiate. How a simple stem cell becomes a highly specialized member of a network, and how those conditions could be recreated in treating disease, is the focus of the Systems Biology of Stem Cells and Reprogramming project. When most human tissues are damaged, the wound is healed by cell division, to grow back skin, muscle or bone. On injury, the injured part is temporarily returned to a less specialized state. Once the signals to keep dividing are gone, the new cells establish different molecular interactions that give them their special functions. Adult nerve cells were previously not thought to regenerate. However, we now know that even in the adult human brain, new nerve cells arise. Exercise, enriched environment, good nutrition, sunlight, and fresh air all help to regenerate nerve cells. Exactly how this happens, is what the SyBoSS research initiative intends to find out. |
| Impact | not currently known |
| Start Year | 2010 |
| Description | SyBoSS |
| Organisation | Helmholtz Association of German Research Centres |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration |
| Collaborator Contribution | Biologists, chemists, physicists and bioinformaticians from five European countries have been engaged by the EU Seventh Framework to work out how stem cells differentiate. How a simple stem cell becomes a highly specialized member of a network, and how those conditions could be recreated in treating disease, is the focus of the Systems Biology of Stem Cells and Reprogramming project. When most human tissues are damaged, the wound is healed by cell division, to grow back skin, muscle or bone. On injury, the injured part is temporarily returned to a less specialized state. Once the signals to keep dividing are gone, the new cells establish different molecular interactions that give them their special functions. Adult nerve cells were previously not thought to regenerate. However, we now know that even in the adult human brain, new nerve cells arise. Exercise, enriched environment, good nutrition, sunlight, and fresh air all help to regenerate nerve cells. Exactly how this happens, is what the SyBoSS research initiative intends to find out. |
| Impact | not currently known |
| Start Year | 2010 |
| Description | SyBoSS |
| Organisation | Max Planck Society |
| Department | Max Planck Institute for Molecular Cell Biology and Genetics |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration |
| Collaborator Contribution | Biologists, chemists, physicists and bioinformaticians from five European countries have been engaged by the EU Seventh Framework to work out how stem cells differentiate. How a simple stem cell becomes a highly specialized member of a network, and how those conditions could be recreated in treating disease, is the focus of the Systems Biology of Stem Cells and Reprogramming project. When most human tissues are damaged, the wound is healed by cell division, to grow back skin, muscle or bone. On injury, the injured part is temporarily returned to a less specialized state. Once the signals to keep dividing are gone, the new cells establish different molecular interactions that give them their special functions. Adult nerve cells were previously not thought to regenerate. However, we now know that even in the adult human brain, new nerve cells arise. Exercise, enriched environment, good nutrition, sunlight, and fresh air all help to regenerate nerve cells. Exactly how this happens, is what the SyBoSS research initiative intends to find out. |
| Impact | not currently known |
| Start Year | 2010 |
| Description | SyBoSS |
| Organisation | Technical University of Denmark |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration |
| Collaborator Contribution | Biologists, chemists, physicists and bioinformaticians from five European countries have been engaged by the EU Seventh Framework to work out how stem cells differentiate. How a simple stem cell becomes a highly specialized member of a network, and how those conditions could be recreated in treating disease, is the focus of the Systems Biology of Stem Cells and Reprogramming project. When most human tissues are damaged, the wound is healed by cell division, to grow back skin, muscle or bone. On injury, the injured part is temporarily returned to a less specialized state. Once the signals to keep dividing are gone, the new cells establish different molecular interactions that give them their special functions. Adult nerve cells were previously not thought to regenerate. However, we now know that even in the adult human brain, new nerve cells arise. Exercise, enriched environment, good nutrition, sunlight, and fresh air all help to regenerate nerve cells. Exactly how this happens, is what the SyBoSS research initiative intends to find out. |
| Impact | not currently known |
| Start Year | 2010 |
| Description | SyBoSS |
| Organisation | Technical University of Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration |
| Collaborator Contribution | Biologists, chemists, physicists and bioinformaticians from five European countries have been engaged by the EU Seventh Framework to work out how stem cells differentiate. How a simple stem cell becomes a highly specialized member of a network, and how those conditions could be recreated in treating disease, is the focus of the Systems Biology of Stem Cells and Reprogramming project. When most human tissues are damaged, the wound is healed by cell division, to grow back skin, muscle or bone. On injury, the injured part is temporarily returned to a less specialized state. Once the signals to keep dividing are gone, the new cells establish different molecular interactions that give them their special functions. Adult nerve cells were previously not thought to regenerate. However, we now know that even in the adult human brain, new nerve cells arise. Exercise, enriched environment, good nutrition, sunlight, and fresh air all help to regenerate nerve cells. Exactly how this happens, is what the SyBoSS research initiative intends to find out. |
| Impact | not currently known |
| Start Year | 2010 |
| Description | SyBoSS |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration |
| Collaborator Contribution | Biologists, chemists, physicists and bioinformaticians from five European countries have been engaged by the EU Seventh Framework to work out how stem cells differentiate. How a simple stem cell becomes a highly specialized member of a network, and how those conditions could be recreated in treating disease, is the focus of the Systems Biology of Stem Cells and Reprogramming project. When most human tissues are damaged, the wound is healed by cell division, to grow back skin, muscle or bone. On injury, the injured part is temporarily returned to a less specialized state. Once the signals to keep dividing are gone, the new cells establish different molecular interactions that give them their special functions. Adult nerve cells were previously not thought to regenerate. However, we now know that even in the adult human brain, new nerve cells arise. Exercise, enriched environment, good nutrition, sunlight, and fresh air all help to regenerate nerve cells. Exactly how this happens, is what the SyBoSS research initiative intends to find out. |
| Impact | not currently known |
| Start Year | 2010 |
| Description | SyBoSS |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration |
| Collaborator Contribution | Biologists, chemists, physicists and bioinformaticians from five European countries have been engaged by the EU Seventh Framework to work out how stem cells differentiate. How a simple stem cell becomes a highly specialized member of a network, and how those conditions could be recreated in treating disease, is the focus of the Systems Biology of Stem Cells and Reprogramming project. When most human tissues are damaged, the wound is healed by cell division, to grow back skin, muscle or bone. On injury, the injured part is temporarily returned to a less specialized state. Once the signals to keep dividing are gone, the new cells establish different molecular interactions that give them their special functions. Adult nerve cells were previously not thought to regenerate. However, we now know that even in the adult human brain, new nerve cells arise. Exercise, enriched environment, good nutrition, sunlight, and fresh air all help to regenerate nerve cells. Exactly how this happens, is what the SyBoSS research initiative intends to find out. |
| Impact | not currently known |
| Start Year | 2010 |
| Description | SyBoSS |
| Organisation | University of Copenhagen |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a Principal Investigator on this collaboration |
| Collaborator Contribution | Biologists, chemists, physicists and bioinformaticians from five European countries have been engaged by the EU Seventh Framework to work out how stem cells differentiate. How a simple stem cell becomes a highly specialized member of a network, and how those conditions could be recreated in treating disease, is the focus of the Systems Biology of Stem Cells and Reprogramming project. When most human tissues are damaged, the wound is healed by cell division, to grow back skin, muscle or bone. On injury, the injured part is temporarily returned to a less specialized state. Once the signals to keep dividing are gone, the new cells establish different molecular interactions that give them their special functions. Adult nerve cells were previously not thought to regenerate. However, we now know that even in the adult human brain, new nerve cells arise. Exercise, enriched environment, good nutrition, sunlight, and fresh air all help to regenerate nerve cells. Exactly how this happens, is what the SyBoSS research initiative intends to find out. |
| Impact | not currently known |
| Start Year | 2010 |
| Description | Thora Karadottir - Carol Brayne |
| Organisation | University of Cambridge |
| Department | Department of Public Health and Primary Care |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir -Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Collaborator Contribution | Collaboration with Carol Brayne - Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Impact | Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Start Year | 2016 |
| Description | Thora Karadottir - Cell Guidance Systems |
| Organisation | Cell Guidance Systems Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Thora Karadottir; Cell culture media development. |
| Collaborator Contribution | Collaboration with Michael Jones; Cell culture media development. |
| Impact | Cell culture media development. |
| Start Year | 2014 |
| Description | Thora Karadottir - Imperial College London |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir; Nature Communications (2015); Investigation of synaptic protein expression in MS lesions. |
| Collaborator Contribution | Collaboration with Richard Reynolds; Nature Communications (2015); Investigation of synaptic protein expression in MS lesions. |
| Impact | Nature Communications (2015); Investigation of synaptic protein expression in MS lesions. |
| Start Year | 2015 |
| Description | Thora Karadottir - Lisa Hall |
| Organisation | University of Cambridge |
| Department | Department of Chemical Engineering and Biotechnology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir - Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Collaborator Contribution | Collaboration with Lisa Hall - Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Impact | Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Start Year | 2016 |
| Description | Thora Karadottir - Max Planck Institute |
| Organisation | Max Planck Society |
| Department | Max Planck Institute for Experimental Medicine |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir; Paper under revision in Nature. Regulation of myelination. |
| Collaborator Contribution | Collaboration with Klaus Nave and Sandra Goebels; Paper under revision in Nature. Regulation of myelination. |
| Impact | Paper under revision in Nature. Regulation of myelination. |
| Start Year | 2012 |
| Description | Thora Karadottir - McGill University |
| Organisation | McGill University |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir; Synaptic communication between axons and OPCs. |
| Collaborator Contribution | Collaboration with Edward Ruthazer; Synaptic communication between axons and OPCs. |
| Impact | Synaptic communication between axons and OPCs. |
| Start Year | 2014 |
| Description | Thora Karadottir - MedImmune |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Thora Karadottir; Support to Glia Club. |
| Collaborator Contribution | Collaboration with Clare Jones; Support to Glia Club. |
| Impact | Support to Glia Club. |
| Start Year | 2014 |
| Description | Thora Karadottir - Michael Coleman |
| Organisation | University of Cambridge |
| Department | Department of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir - Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Collaborator Contribution | Collaboration with Michael Coleman - Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Impact | Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Start Year | 2016 |
| Description | Thora Karadottir - Numedicus |
| Organisation | Numedicus Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Thora Karadottir; Seed fund from SCI Testing licenced drugs for advancing repair in MS. |
| Collaborator Contribution | Collaboration with David Cavalla; Seed fund from SCI Testing licenced drugs for advancing repair in MS. |
| Impact | Seed fund from SCI Testing licenced drugs for advancing repair in MS. |
| Start Year | 2013 |
| Description | Thora Karadottir - Steven Lee |
| Organisation | University of Cambridge |
| Department | Department of Chemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir - Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Collaborator Contribution | Collaboration with Steven Lee - Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Impact | Investigation into white matter dysfunction underpinning Alzeheimer's disease. |
| Start Year | 2016 |
| Description | Thora Karadottir - University of Bufallo |
| Organisation | University at Buffalo |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir; Investigation of the electrophysiological properties of human OPCs. |
| Collaborator Contribution | Collaboration with Fraser Sim and Gabriella Popescu; Investigation of the electrophysiological properties of human OPCs. |
| Impact | Investigation of the electrophysiological properties of human OPCs. |
| Start Year | 2014 |
| Description | Thora Karadottir - University of Cambridge (BRC - Colin Watts) |
| Organisation | National Institute for Health Research |
| Department | NIHR Cambridge Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir; Combined PhD Student. Regulation of glioma cell proliferation. |
| Collaborator Contribution | Collaboration with Colin Watts; Combined PhD Student. Regulation of glioma cell proliferation. |
| Impact | Combined PhD Student. Regulation of glioma cell proliferation. |
| Start Year | 2013 |
| Description | Thora Karadottir - University of Cambridge (BRC) |
| Organisation | National Institute for Health Research |
| Department | NIHR Cambridge Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir; Paper submitted. Contribution of OPCs to frontal dementia. |
| Collaborator Contribution | Collaboration with Maria-Grazia Spillantini; Paper submitted. Contribution of OPCs to frontal dementia. |
| Impact | Paper submitted. Contribution of OPCs to frontal dementia. |
| Start Year | 2013 |
| Description | Thora Karadottir - University of Cambridge (BRC-Andras Lakatos) |
| Organisation | University of Cambridge |
| Department | Centre for Trophoblast Research |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir; Paper in Nature Communications (2014). Reactivity of astrocytes - regulation of synaptic inputs. |
| Collaborator Contribution | Collaboration with Andras Lakatos; Paper in Nature Communications (2014). Reactivity of astrocytes - regulation of synaptic inputs. |
| Impact | Paper in Nature Communications (2014). Reactivity of astrocytes - regulation of synaptic inputs. |
| Start Year | 2011 |
| Description | Thora Karadottir - University of Oslo |
| Organisation | University of Oslo |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir;Paper in Neuroscience (2014) and ongoing work; Changes in white matter with age. |
| Collaborator Contribution | Collaboration with Kristine Waldhovd; Paper in Neuroscience (2014) and ongoing work; Changes in white matter with age. |
| Impact | Paper in Neuroscience (2014) and ongoing work; Changes in white matter with age. |
| Start Year | 2013 |
| Description | Thora Karadottir - University of Oxford |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Thora Karadottir; Paper in Neuroscience (2014) and ongoing work. Structural changes in white matter with learning. |
| Collaborator Contribution | Collaboration with Heide Johansen-Berg; Paper in Neuroscience (2014) and ongoing work. Structural changes in white matter with learning. |
| Impact | Paper in Neuroscience (2014) and ongoing work. Structural changes in white matter with learning. |
| Start Year | 2014 |
| Description | Tony Green - EBI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Tony Green; Role of JAK2 in splicing. |
| Collaborator Contribution | Collaboration with John Marioni; Role of JAK2 in splicing. |
| Impact | Role of JAK2 in splicing. |
| Start Year | 2013 |
| Description | Tony Green - ETH |
| Organisation | ETH Zurich |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Tony Green; Video imaging in JAK2 V617F HSCs (ongoing) manuscript in preparation. |
| Collaborator Contribution | Collaboration with Timm Schroeder; Video imaging in JAK2 V617F HSCs (ongoing) manuscript in preparation. |
| Impact | Video imaging in JAK2 V617F HSCs (ongoing) manuscript in preparation. |
| Start Year | 2011 |
| Description | Tony Green - Imperial College London |
| Organisation | Imperial College London |
| Department | Centre for Haematology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Tony Green; Effect of JAK2 mutation on stem cell localisation. |
| Collaborator Contribution | Collaboration with Cristina Lo Celso; Effect of JAK2 mutation on stem cell localisation. |
| Impact | Effect of JAK2 mutation on stem cell localisation. |
| Start Year | 2013 |
| Description | Tony Green - Micky Tortorella |
| Organisation | Chinese Academy of Sciences |
| Department | Guangzhou Institute of Biomedicine and Health |
| Country | China |
| Sector | Public |
| PI Contribution | Novel therapies for myeloproliferative neoplasms |
| Collaborator Contribution | Novel therapies for myeloproliferative neoplasms |
| Impact | None yet |
| Start Year | 2018 |
| Description | Tony Green - Sanger |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Tony Green; Generation and characterization of the CRISPR guide RNA libraries. |
| Collaborator Contribution | Collaboration with Kosuke Yusa; Generation and characterization of the CRISPR guide RNA libraries. |
| Impact | Generation and characterization of the CRISPR guide RNA libraries. |
| Start Year | 2016 |
| Description | Tony Green - University of Oxford |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Tony Green; Role of NuRD in haematopoiesis: mouse models for MPN transformation. |
| Collaborator Contribution | Collaboration with Stein Eirik Jacobsen and Adam Mead; Role of NuRD in haematopoiesis: mouse models for MPN transformation. |
| Impact | Role of NuRD in haematopoiesis: mouse models for MPN transformation. |
| Start Year | 2013 |
| Description | Tony Green - University of Veterinary Medicine, Vienna |
| Organisation | University of Veterinary Medicine Vienna |
| Country | Austria |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Tony Green; JAK/STAT transcriptional programs. |
| Collaborator Contribution | Collaboration with Veronika Sexl; JAK/STAT transcriptional programs. |
| Impact | JAK/STAT transcriptional programs. |
| Start Year | 2013 |
| Description | Tony Green - Walter & Eliza Institute of Medical Research |
| Organisation | The Walter and Eliza Hall Institute of Medical Research (WEHI) |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Tony Green; Mouse models for MPN transformation. |
| Collaborator Contribution | Collaboration with Warren Alexander; Mouse models for MPN transformation. |
| Impact | Mouse models for MPN transformation. |
| Start Year | 2011 |
| Description | Tony Green - Weill Cornell Medical College |
| Organisation | Cornell University |
| Department | Weill Cornell Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Tony Green; Joint research project. |
| Collaborator Contribution | Collaboration with Ari Melnick; Joint research project. |
| Impact | Joint research project. |
| Start Year | 2011 |
| Title | Cell cycle inhibition to improve gene therapy |
| Description | Cell cycle inhibition to improve gene therapy |
| IP Reference | |
| Protection | Copyrighted (e.g. software) |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | NA |
| Title | METHODS AND COMPOSITIONS FOR ENHANCING CARDIOMYOCYTE MATURATION AND ENGRAFTMENT |
| Description | Provided herein are methods and compositions comprising cardiomyocytes and epicardial cells for the treatment of cardiac disease. |
| IP Reference | WO2018170280 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Yes |
| Impact | Provided herein are methods and compositions comprising cardiomyocytes and epicardial cells for the treatment of cardiac disease. |
| Title | Novel marker for naïve pluripotent cells |
| Description | Novel marker SUSD2 for naïve pluripotent cells. |
| IP Reference | GB1804618.5 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Yes |
| Impact | No notable impact. |
| Title | PLURIPOTENT STEM CELLS |
| Description | The invention provides processes for producing or propagating a formative stem (FS) cell line, from one or more precursor pluripotent stem cells, which process comprises: (a) providing a one or more precursor pluripotent stem cells; (b) culturing the precursor pluripotent stem cells in formative stem cell culture media. The formative stem cell culture media comprises limited amounts of activin and exogenous fibroblast growth factor, but includes a Wnt inhibitor, and typically a retinoic acid receptor inhibitor. The invention further provides related materials and methods for use in preparing and utilising FS cell lines. |
| IP Reference | WO2018138281 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | No |
| Impact | There is no notable impact. |
| Title | Resetting pluripotent stem cells |
| Description | n.a |
| IP Reference | |
| Protection | Patent application published |
| Year Protection Granted | 2014 |
| Licensed | No |
| Impact | n.a |
| Title | STEM CELLS FROM THE MAMMALIAN NEURAL PLATE |
| Description | The present invention relates to methods for deriving novel stem cells from the mammalian early neural plate. |
| IP Reference | WO2013156768 |
| Protection | Patent application published |
| Year Protection Granted | 2013 |
| Licensed | No |
| Impact | n.a |
| Title | TREATMENT FOR DEMYELINATING DISEASE |
| Description | This invention relates to the use of AMPK agonists, such as metformin to, restore the responsiveness of aged oligodendrocyte progenitor cells (OPCs) to differentiation factors. This may be useful in promoting oligodendrocyte differentiation and increasing the remyelination of neuronal axons, for example in the treatment of demyelinating diseases, such as multiple sclerosis (MS). Therapeutic combinations comprising AMPK agonist and a differentiation factor and therapeutic uses thereof are provided. |
| IP Reference | WO2019206419 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | Treatment for Demyelinating Disease |
| Title | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies - Brian Huntly |
| Description | This is an open-label repeat dose, multicenter, 2-part study to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for GSK525762 given once-daily (QD) orally. Part 1 of the study is a dose escalation phase to select the recommended Part 2 dose (RP2D) based on the safety, PK, and PD profiles observed after oral administration of GSK525762. Eligible subjects with select relapsed refractory hematological malignancies (acute myeloid leukemia [AML], non-Hodgkin's Lymphoma [NHL]and multiple myeloma [MM]), will be enrolled in the QD and/or BID dosing cohorts until a MTD is established. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent. . Upon determination of the MTD, twice daily (BID) dosing cohorts may be opened to collect additional safety data and evaluate the preliminary efficacy of GSK525762 administered BID. Part 2 will explore clinical activity at the MTD or RP2D; separate expansion cohorts will be planned for acute myeloid leukemia (AML), non-Hodgkin's Lymphoma (NHL, including an exploratory sub-cohort of subjects with myc and B-Cell Leukemia (BCL)2 and/or BCL6 rearrangements/overexpression [double- and triple-hit lymphoma]), and multiple myeloma (MM). This is the first study of this agent to be conducted in subjects with these relapsed and/or refractory hematological malignancies for which no standard therapies are anticipated to result in a durable remission. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | The results of this study are still being evaluated, but this is the first study of this agent to be conducted in subjects with these relapsed and/or refractory hematological malignancies for which no standard therapies are anticipated to result in a durable remission. |
| URL | https://clinicaltrials.gov/show/NCT01943851 |
| Title | A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) - Roger Barker |
| Description | This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether neflamapimod can reverse hippocampal dysfunction in patients with early-stage HD, as assessed by the virtual water-maze-test for evaluating spatial learning and selected tests on the Cambridge Neuropsychological Test Automated Battery (CANTAB). |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2020 |
| Development Status | On hold |
| Clinical Trial? | Yes |
| Impact | The results of this clinical trial are still being assessed. |
| URL | https://clinicaltrials.gov/ct2/show/NCT03980938 |
| Title | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease - Roger Barker |
| Description | This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in patients with manifest Huntington's disease (HD). |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | This clinical trial has not yet been completed. |
| URL | https://clinicaltrials.gov/ct2/show/NCT03761849 |
| Title | ADIPOA-2 Clinical Trial - Andrew McCaskie |
| Description | Osteoarthritis (OA) is an incurable and debilitating disease. It has been identified as the world's eleventh highest contributor to disability and affects over 70 million Europeans. There is currently no treatment to prevent progression of the disease. In the absence of effective pharmacological, biological or surgical treatment options, cellular therapies using mesenchymal stem/stromal cells (MSCs) have emerged as potential treatments for this condition. Autologous adipose-derived mesenchymal stromal cells (ASCs) are an attractive option for these cellular therapies because of the abundance of tissue, high frequency of MSCs, and minimally invasive harvest procedure. The EU consortium ADIPOA has shown in a 'first in man' 2-centre Phase I safety study that intraarticular injection of a single dose of autologous ASCs to the knee (18 patients, 12 month follow-up) was well-tolerated, had no adverse effects, and resulted in an improvement in pain score and functional outcome. ADIPOA-2 will build on the work of ADIPOA to deliver a large-scale clinical trial in regenerative medicine for OA. The purpose of the project is to design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) ACSs in the treatment of advanced OA of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipoaspiration. ADIPOA-2 will carry out a multi-centre, randomized clinical trial comparing the use of culture-expanded, autologous adult ASCs in subjects with knee OA with injected Hyaluronan (another widely used therapeutic approach for knee degeneration). This study will involve two major elements: the production of consistent batches of high-quality autologous ASCs under GMP-compliant conditions and the delivery of these cell doses to patients in a trial which will meet all national and European regulatory and ethical standards and which will provide a definitive demonstration of the safety and efficacy of ASCs as a therapy for osteoarthritis. |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | ADIPOA-2 will build on the work of ADIPOA to deliver a large-scale clinical trial in regenerative medicine for OA. The purpose of the project is to design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) ACSs in the treatment of advanced OA of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipoaspiration. |
| URL | https://clinicaltrials.gov/show/NCT02838069 |
| Title | An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies - Roger Barker |
| Description | Entry into the study should occur at the time the participant completes participation in one of the preceding studies. Upon completion of the inclusion visit, eligible participants will receive either RO7234292 (RG6042) every 8 weeks (Q8W) or RO7234292 (RG6042) every 16 weeks (Q16W) by bolus intrathecal injection. Participants who received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q8W. Participants who previously received open-label of RO7234292 Q8W in a preceding study or are currently receiving RO7234292 Q8W in this study will receive RO7234292 Q8W. Participants who previously received placebo, or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q8W. Participants who previously received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q8W will receive open-label RO7234929 Q8W. Participants who received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q8W. Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Clinical trial has not yet been completed. |
| URL | https://clinicaltrials.gov/ct2/show/NCT03842969 |
| Title | Bexarotene MS (Robin Franklin) |
| Description | A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial. Ongoing |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Clinical trial - ongoing. |
| URL | https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003145-99 |
| Title | DLBCL Interim Response Evaluation for Customised Therapy (DIRECT) - Dan Hodson |
| Description | The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an integrated response evaluation determined early in first-line therapy. Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor. Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable. Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | It is too early to describe the impacts of this clinical trial, but the trial seeks to improve diagnostic measures related to high-grade B cell lymphoma. |
| URL | https://clinicaltrials.gov/ct2/show/NCT04226937 |
| Title | Dopaminergic gene therapy (Roger Barker) |
| Description | This study consists of two parts. Part A is an open-label dose-escalation phase in which participants are enrolled in cohorts and will receive one of approximately three escalating doses of OXB-102 (AXO-Lenti-PD). Part B is a randomized, double-blind phase in which participants will be randomized to either an active group receiving the selected dose from Part A, or to a control group receiving an imitation surgical procedure (ISP). |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | This clinical trial is ongoing, and its potential impacts have not yet been fully assessed. |
| URL | https://clinicaltrials.gov/show/NCT03720418 |
| Title | Effects of Tamoxifen (Simon Mendez-Ferrer) |
| Description | Myeloproliferative neoplasms (MPNs) are blood cancers which affect the normal production of blood cells from the bone marrow. They are caused by changes (mutations) in blood stem cells, frequently in the genes that produce proteins called JAK2, CALR or MPL. MPNs have a risk of developing to an acute leukaemia (a more advanced stage of disease) and currently has no effective cure, apart from bone marrow transplantation which is not possible for many patients. Recent work in mouse studies has suggested that tamoxifen, a drug widely used to treatment breast cancer, may reduce the number of mutated cells by mimicking oestrogen (a female sex hormone) which has a role in the survival and production of new stem cells that give rise to blood cancers. In these studies, tamoxifen prevented the excessive production of blood cells by restoring normal levels of cell death in the mutated cells. This is a single arm, multicentre phase II trial designed to assess if adding tamoxifen to patients receiving therapy for their MPN reduces the number of mutated cells found in the blood by = 50% after 24 weeks of treatment compared to the start of the study. Collection of blood and bone marrow samples will also allow laboratory researchers to study the biological effects of tamoxifen and how this correlates with the patient's disease and response to therapy. Patients will receive treatment with 20mg once daily (oral tablet) of tamoxifen with their normal therapy for their MPN. 42 patients will be recruited from 13-15 UK centres over 12 months. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | The results of this clinical trial are still being evaluated and should be published in the near future. |
| URL | https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005497-38 |
| Title | Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease - Roger Barker |
| Description | The study is designed to assess the long term tolerability of ProSavin and whether it is safe and efficacious in patients administered ProSavin from the PS1/001/07 study. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | The results of this clinical trial are still under assessment. |
| URL | https://clinicaltrials.gov/ct2/show/NCT01856439 |
| Title | Long-term follow-up study (David Rowitch) |
| Description | Long-Term Follow-Up Safety and Preliminary Efficacy Study of Human Central Nervous System Stem Cell (HuCNS-SC®) Transplantation in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD) - Closed. |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2016 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | In assessment. |
| URL | https://clinicaltrials.gov/show/NCT01391637 |
| Title | RESTORE: Recovery and Survival of Stem Cell Originated Red Cells - Cedric Ghevaert/NHS Blood and Transplant |
| Description | A single centre randomised, controlled phase I cross-over trial in healthy volunteers to assess the recovery and survival of a mini-dose of red blood cells derived from CD34+cells isolated from adult blood vs standard donated red blood cells. Randomised, single blind, cross-over design to compare the recovery and survival of red blood cells manufactured from CD34+ cells isolated from adult blood compared with standard donated red blood cells. The order in which each recipient receives the standard or manufactured red blood cells is randomised and recipients will be blinded to that order. |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | There are a small number of patients with rare blood group types for whom NHS Blood and Transplant cannot meet the transfusion requirements. New red blood cells can be grown from human blood stem cells in the laboratory. We hope that this will provide us with a novel transfusion product for these patients in the future, some of whom require regular transfusions throughout life (e.g. for thalassemia or sickle cell disease). |
| URL | https://www.nhsbt.nhs.uk/clinical-trials-unit/current-trials-and-studies/restore/ |
| Title | TRANSEURO (Roger Barker) |
| Description | An Open Label Study to Assess the Safety and Efficacy of Neural Allo-Transplantation With Fetal Ventral Mesencephalic Tissue in Patients With Parkinson's Disease |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2013 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | Under assessment. |
| URL | https://clinicaltrials.gov/show/NCT01898390 |
| Company Name | STROMA BIOSCIENCES LIMITED |
| Description | A company whose goal is discovering novel stroma-intrinsic targets and therapeutics specifically targeting these mechanisms in a broad range of diseases. |
| Year Established | 2020 |
| Impact | A company whose goal is discovering novel stroma-intrinsic targets and therapeutics specifically targeting these mechanisms in a broad range of diseases. |
| Company Name | CamBioScience |
| Description | CamBioScience Limited provides intensive training courses in breakthrough life science technologies for professionals in academia and industry. |
| Year Established | 2015 |
| Impact | To date the company has trained an international customer base of professional scientists from over 60 leading academic and industrial institutions and more than 30 countries worldwide. As of 2017 CamBioScience began scaling-up its capacity to deliver breakthrough course content via the construction of a bespoke cloud-based e-learning platform aimed at disrupting cutting-edge knowledge acquisition and assessment in the wider life science sectors (biotechnology, bioengineering, biopharma and medtech). |
| Website | https://www.cambioscience.com/ |
| Company Name | BILITECH LTD |
| Description | Cell based therapy for cholangiopathies. |
| Year Established | 2017 |
| Impact | None yet. |
| Company Name | CELLADVICE LTD |
| Description | Consultancy for companies involved in transfusion product or cell therapies |
| Year Established | 2019 |
| Impact | None yet |
| Company Name | DefiniGEN |
| Description | DefiniGEN was founded in April 2013 to industrialize the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke's Hospital and in addition has in-licensed the Yamanaka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc. |
| Year Established | 2012 |
| Impact | The company has world-leading expertise in the area of iPSC production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments. In addition the technology platform utilises fully defined and humanized conditions required for the development of regenerative medicine cellular therapies. |
| Website | https://www.definigen.com/ |
| Company Name | HEPATOTARGET THERAPEUTICS LTD. |
| Description | Development of stem cell differentiation technology to manufacture mature hepatocytes as a cell therapy for liver disease. |
| Year Established | 2019 |
| Impact | None yet |
| Description | 25 Years of Embryonic Stem Cells in Cambridge |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Discussion post event |
| Year(s) Of Engagement Activity | 2006 |
| Description | 4L Trophy Rally supporting Enfants du Desert |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | PhD Students Marion Perrin and Daniel Bode participated in the 4L Trophy Rally supporting Enfants du Desert. They took messages about stem cell research and tried to engage with audiences along the way. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.cambridgeindependent.co.uk/news/cambridge-phd-students-to-tackle-the-4l-trophy-rally-the... |
| Description | AbCam - Rediscovering Pluripotency |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | The talk encouraged thinking and discussions n.a |
| Year(s) Of Engagement Activity | 2011 |
| URL | http://www.abcam.com/index.html?pageconfig=resource&rid=13408 |
| Description | An Interview with Austin Smith |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | An interview piece by Caterina Vicente, originally publised in Development; republised by, The Node & EuroStemCell and widely shared on Twitter. Outcome: This activity contributes to our strategic objective to engage hard to reach adults |
| Year(s) Of Engagement Activity | 2015 |
| Description | Authored materials for EuroStemCell |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Professor Austin Smith authored materials for EuroStemCell. These were used on their website which is a source of information about Stem Cells. This website is promoted to the general public. |
| Year(s) Of Engagement Activity | 2014 |
| Description | BBC Science & Technology |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Commentary for BBC Science & Technology, Jan 2018 |
| Year(s) Of Engagement Activity | 2018 |
| Description | BRAINFest |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | As part of the first ever Cambridge BRAINFest the Institute took along an exhibit on 'Stem cells and the Brain' to this vibrant take-over of Cambridge Corn Exchange. Researchers from the Káradóttir and Franklin labs developed a set of interactive hands on activities to initiate conversations with the public about; ?Why insulating the neurons in your brain with 'myelin' is so important. ?How brain stem cells play their part in myelination. ?What impact stem cell research is having on new therapies for myelin-related diseases such as Multiple Sclerosis. In addition, Professor Roger Barker spoke about his pioneering Parkinson's research in the opening night showcase for the Festival on 23 June. BRAINFest was organised by Cambridge Neuroscience and ran from 23 - 25 June 2017. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Black Women in Science videos |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Seun Ogundele received Public Engagement seed funding to make a series of videos about "Black Women in Science", which have been released on Social media. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.youtube.com/channel/UCeky9avt81tiHJuqE_RGzrg |
| Description | Cambridge Science Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Stem Cell Institute researchers are taking part in several events at the annual Cambridge Science Festival. ?Stanley Strawbridge (Smith group), Comedian, The Variables Present...an evening of science variety ?Dr Joo-Hyeon Lee, Panel member, Mini-me: How 3D Organoids are Revolutionising Research ?Alisa Molotova (Franklin group), Comedian, Bright Club ?Hands on volunteers, Stem Cell Robots ?Dr Brian Hendrich, Panel member, Epigenetics: DNA Does Not Account for everything ?Hands on volunteers, Stem Cell Robots |
| Year(s) Of Engagement Activity | 2017 |
| Description | Cambridge Science Festival |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | 120 public attended the presentation and slide show. There was a Q&A at the end of the talk. n/a |
| Year(s) Of Engagement Activity | 2013 |
| Description | Cambridge Science Festival 2015 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Ge Guo and Sam Myers from the Smith Lab took part in the Cambridge Science Festival 2015 - the theme was Differentiate Me. 'Differentiate Me' was a hands on exhibit at the Cambridge Guildhall designed by SCI researchers. It involved 3 activity stations, suitable for a wide age-range, all of which aimed to teach the fundamental principle of differentiation: Cell transformers - a mock wet lab activity where children dress in lab-coats and goggles The Blood Station - modelling different types of cell in play-doh Race to Differentiate - a multi-player custom designed board game Outcome: We had positive face-to-face reactions with hundreds of children and their families, which helps to meet our strategic objective to engage Cambridge families. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Cardiff Scientific Society |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Presented the Sir Martin Evans Lecure to Cardiff Scientfic Society members. n/a |
| Year(s) Of Engagement Activity | 2012 |
| Description | Cedric Ghevaert - The Naked Scientist |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview for the Naked Scientist podcast by Institute PI Cedric Ghevaert about his research into making blood in the lab |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.thenakedscientists.com/articles/interviews/making-blood-lab |
| Description | Cherry Hinton Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Scientists from the Stem Cell Institute went for the first time to the Cherry Hinton Festival in Cambridge to discuss their research, and get people thinking about the power and potential of stem cells. Make your own playdoh cell to take home, learn how cells are looked after in the laboratory, and experiment with turning 'body cells' back into 'stem cells' (as if by magic!). Led by Thorsten Klampfl and Jacob Grinfeld (Green lab), and Justyna Rak (Méndez-Ferrer lab). |
| Year(s) Of Engagement Activity | 2017 |
| Description | Daniel Hodson - Cambridge Science Festival |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Institute PI Daniel Hodson gave a talk a participated in a panel discussion about the use of human tissue within research. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Dinner at the British Embassy, Switzerland |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | n.a |
| Year(s) Of Engagement Activity | 2010 |
| Description | Elisa Laurenti - EHA |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Expert Interview at the European Hematology Association Annual meeting; topic: "Stem cells in steady state and under stress" by Institute PI Elisa Laurenti |
| Year(s) Of Engagement Activity | 2019 |
| Description | Elisa Laurenti and Brian Huntly - Pint of Science |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Talk and discussion by Institute PIs Elisa Laurenti and Brian Huntly, Pint of Science - "The Dark Side of Blood" |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://pintofscience.co.uk/event/the-dark-side-of-blood |
| Description | Elisa Laurenti- Cambridge Independent |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview for Cambridge Independent about collaboration by Institute PI Elisa Laurenti with the Rosie Hospital for the use of donated cord blood |
| Year(s) Of Engagement Activity | 2019 |
| Description | European Researchers Night in Ely |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The Institute organised some engagement activities for the European Researchers Night in Ely, to raise awareness of stem cell research. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Filmed interview - cell therapy |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview encouraged discussions n.a |
| Year(s) Of Engagement Activity | 2009 |
| Description | Franklin lab - Cambridge Science Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The Franklin lab organised the event "What a nerve" for the Cambridge Science Festival, where they used hands on activities to explain their research on multiple sclerosis. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Game Jam - Smith Lab |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | At this pilot event, 20 games developers were offered a crash course in stem cell biology, including a hands-on tour of the laboratories. They then had 48 hours to create a new computer game on the theme 'Destiny & Decisions' in stem cell research. Members of the Smith lab took the game developers on a tour of the lab and provided them with the crash course of stem cells. The smith lab members were also available on the day to answer questions or help provide scientific content. Outcome: This activity contributes to our strategic objective to engage hard to reach adults |
| Year(s) Of Engagement Activity | 2015 |
| Description | Hosted Nuffield student placement |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | 3 A Level students undertook 4 week research placements to experience working in a laboratory environment. Including talks, tours & visits to several labs. The Smith lab hosted a Nuffield student for 4 weeks. The students were with the lab for 4 weeks and shadowed the scientists in the labs, They also arranged times for the students to read journals and attend seminars. At the end of the 4 weeks, the students had to produce a poster on the work they had conducted over the four weeks. Austin was the overall supervisor for his student, however 4 of his lab members were daily supervisors of the student. The student in the Smith Lab reported a high level of learning and personal development as well as an increased interest in studying biology. This activity contributes to our strategic objective to engage under-served schools and young people |
| Year(s) Of Engagement Activity | 2015 |
| Description | Ingo Ringshausen - CRUK fundraising |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Institute PI Ingo Ringshausen took part in the Burghley Park and Peterborough Ladies Meeting CRUK fundraising organisation. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Ingo Ringshausen - Cambridgeshire CLL patient support group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Institute PI Ingo Ringshausen gave a talk to Cambridgeshire CLL patient support group. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Interview for AAAS - Science Magazine, Berlin |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | n/a |
| Year(s) Of Engagement Activity | 2012 |
| Description | Interview for Agence France Presse |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | n/a |
| Year(s) Of Engagement Activity | 2012 |
| Description | Interview for the University of Cambridge Radio |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Interview for the University of Cambridge Radio Station Promoted the work of the Stem Cell Institute |
| Year(s) Of Engagement Activity | 2014 |
| Description | Interview with Alice Park, Time Magazine |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | increased awareness of Stems Cells in the media n.a |
| Year(s) Of Engagement Activity | 2014 |
| Description | Interview with Anna Azvolinsky, Science |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Spread information about the Stem Cell Institute n.a |
| Year(s) Of Engagement Activity | 2014 |
| Description | Interview with BBC Radio Cambridge |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Sparked interest in Stem Cell Biology n.a |
| Year(s) Of Engagement Activity | 2014 |
| Description | Interview with Fabian Ketschmer, Der Standard |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Increased awareness of the UK Stem Cell Science developments n.a |
| Year(s) Of Engagement Activity | 2013 |
| Description | Interview with Heart Radio |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview with the local radio station to discuss Stem Cells and the work being done in this field Increased awareness of the work being done in Cambridge in the Stem Cell field. |
| Year(s) Of Engagement Activity | 2012 |
| Description | Interview with Rob Stein, NPR |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Increased awareness around Stem Cell Biology not known |
| Year(s) Of Engagement Activity | 2014 |
| Description | Interview with The Asahi Shimbun |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | The Asahi Shimbun is one of the five national newspapers in Japan - after the interview this promoted the relationship between Stem Cell Science in the UK and Japan Increased awareness of UK Stem Cell Science in Japan |
| Year(s) Of Engagement Activity | 2013 |
| Description | Interviews with BBC Radio and Cambridge News - Robin Franklin |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Robin Franklin - Interviews with BBC Radio Cambridgeshire, Cambridge news and Anglia News (evening) discussing stem cell therapies in MS. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Judge at the game jam |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | At this pilot event, 20 games developers were offered a crash course in stem cell biology, including a hands-on tour of the laboratories. They then had 48 hours to create a new computer game on the theme 'Destiny & Decisions' in stem cell research. Austin Smith was on the judging panel. Outcome: This activity contributes to our strategic objective to engage hard to reach adults |
| Year(s) Of Engagement Activity | 2015 |
| Description | Kevin Chalut and Robin Franklin - The Naked Scientist |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Kevin Chalut and Robin Franklin were interviewed for The Naked Scientist podcast, talking about their research into reversing ageing in the brain. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.thenakedscientists.com/articles/interviews/reversing-ageing-brain |
| Description | Lab grown cells |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | A group of blood researchers, led by Dr Cedric Ghevaert from the Wellcome - MRC Cambridge Stem Cell Institute, are exploring new ways to produce red blood cells and platelets from stem cells in the laboratory. These cells have the potential to revolutionise transfusion medicine, but what questions do the public and blood donors have for the scientists behind this pioneering work? Video shows the answers. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Lecture at Croucher Foundation Advanced Study Institute |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Lecture prompted discussions and questions Have been invited back in Jan 2014 to present again |
| Year(s) Of Engagement Activity | 2013 |
| Description | Literary Festival 2014 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The talk resulted in increased interest in the work of the Stem Cell Institute Asked for participation in the next event |
| Year(s) Of Engagement Activity | 2014 |
| Description | Ludovic Vallier - Cambridge Science Festival |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Institute PI Ludovic Vallier participated in a talk and panel discussion for the Cambridge Science Festival with the Immunology Network about the "Future of Medicine" |
| Year(s) Of Engagement Activity | 2019 |
| Description | Newmarket All Saints Concert |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Institute PI Cedric Ghevaert organised a Charity concert at All Saints Church in Newmarket, raising funds for East Anglian Air Ambulance. The lab took some materials to engage the audience with stem cell research. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Oxbridge Academic Programmes - Tour |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | 15 sixth form students were invited for a lab tour of the lab. Stanley Strawbridge (Smith Lab) showed the student around the lab and talked them through the work which is conducted in the smith lab. |
| Year(s) Of Engagement Activity | 2015 |
| Description | PER Awards |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | University of Cambridge, Vice-Chancellor's Public Engagement with Research Awards - member of the judge panel. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Photoshoot - 'The Philanthropist' magazine |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | An interview and photo-shoot for Cambridge University's 'The Philanthropist' magazine - a feature about the work of the Cambridge Stem Cell Institute Increased awareness of the work of the Cambridge Stem Cell Institute |
| Year(s) Of Engagement Activity | 2012 |
| Description | Pint of Science 2015 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Pint of Science hosts scientific talks and events in various pubs around the world. There were several venues in Cambridge, but the main stem cell talks were at the Panton Arms. Stanley Strawbridge (PhD student in the smith lab) was on the committee and helped organise the talks across Cambridge. He was also responsible for promoting the event to the general public. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Public Engagement Workshop - Wellcome Trust |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | sparked discussion of the issues facing regarding public engagement and how the Wellcome Trust could help to overcome difficulties or barriers. n/a |
| Year(s) Of Engagement Activity | 2013 |
| Description | Rachford Lecture - Cincinnati Children's Hospital |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | Large question and answer session after the talk - talk promoted in depth discussions n.a |
| Year(s) Of Engagement Activity | 2013 |
| Description | Regenerator - A Stem Cell Brew |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Seed fund project - Regenerator, a CSCI ale, was developed in collaboration with local brewery Moonshine. The beer was launched at Cambridge Beer Festival in an effort to bring stem cell science to new "harder to reach" groups. A team of 5 PhD students attended the Festival equipped with "conversation starters" including pipette samples of the beer and were able to engage people in face to face discussions about stem cells and their future potential. Following a successful launch, Regenerator went "on tour" in Autumn 2017 across five Cambridgeshire pubs, accompanied by informal science cafes, comedy and stem-cell pub quizzes. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Robin Franklin - BBC News |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | BBC News - interview about Metformin paper reporting Diabetes drug reverses cell ageing and could stop multiple sclerosis. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Roger Barker - PD Open Day |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Parkinson's disease open day organised by Institute PI Roger Barker, engaging with the general public and patient groups talking about his research into Parkinson's disease. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Sanjay Sinha - BBC Look East |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview on BBC Look East about new research published in Nature Biotechnology on heart regeneration by Institute PI Sanjay Sinha |
| Year(s) Of Engagement Activity | 2019 |
| Description | School visit, London |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | 800 A-level biology students attended a lecture on Stem Cell Research as part of their annual programme which is called 'A Student's Guide to DNA and Genetics'. After providing a similar talk in 2009 The Institute of Education in London requested a return lecture. |
| Year(s) Of Engagement Activity | 2009,2011 |
| Description | Science Talk |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Public presentation on Stem Cells 'Hope or Hype' as part of the Cambridge Science Festival n/a |
| Year(s) Of Engagement Activity | 2013 |
| Description | Science uncovered at the Natural History Museum |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Masaki Kinsohita from the Smith Lab (Post doctoral researcher). For one evening only, the Natural History Museum will be taken over by scientists! Interactive activities and exhibits throughout the museum will provide an opportunity to learn about the latest research Outcome: This activity contributes to our strategic objective to engage hard to reach adults |
| Year(s) Of Engagement Activity | 2015 |
| Description | Simon Buczacki - CAST Students |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Institute PI Simon Buczacki gave a talk to CAST students about the use of animals in research. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Sinha lab - Cambridge Science Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The Sinha lab organised a stand for the public showing their research into cardiovascular health for the Cambridge Science Fetsival. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Speaker at 'See inside the Cambridge Stem Cell Institute' 2015 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | 15 members of the general public were invited to the Stem Cell Institute for a tour of the facilities. Members of the Smith Lab showed the general public around the lab space and gave demonstrations about the different facilities we have on site. Austin Smith gave an introduction to the tour group about the Institute and also did a question and answer session at the end, |
| Year(s) Of Engagement Activity | 2015 |
| Description | Srinjan Basu - Day school |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Institute PI Srinjan Basu gave a talk on "Epigenetics: more than just our genes" at the Institute of Continuing Education. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Stem Cell Exchanges |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Podcasts Mariana Alves (Silva Group) interviewed a selection of our SCI Principal Investigators for a series of 11 podcasts. The podcasts seek to uncover each group leaders approach to research and the impact their discoveries are having on our understanding of stem cells and disease. Artwork Katie Tremble (Silva Group) built a partnership with Cambridge Pint of Science to pair the 11 podcast scientists with Cambridge-based artists over a six-week period, starting in May 2017. The artists and scientists will be encouraged to work collaboratively to create a piece/s of artwork inspired by stem cell science. The artworks were exhibited at a public showcase event in Michaelhouse Cafe on 19th June - 1st July with an exhibition finale featuring performance poets on Thursday 29th June. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.stemcells.cam.ac.uk/public/past-events-and-projects/2017/exchanges-at-the-stem-cell-inst... |
| Description | Stem Cell Podcast |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | The interview was for the Stem Cell podcast which is listened to by more than 20,000. This was a great platform to discuss a recently published paper which allowed a wide audience to receive information about the paper. Increase awareness of the published paper |
| Year(s) Of Engagement Activity | 2014 |
| Description | The layman challenge 'explaining work to a group of non-scientists' |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Professor Smith took part in the The layman challenge. He had to explain his work to a group of non-scientists, this was so the general public could understand his research without needing a scientific background. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Tony Green - JCBC artwork |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Institute PI Tony Green worked with various artists to develop artwork for the Institute new building. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Variables Science Comedy nights |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Trained in the 'dark arts' for the first time by the Institute's own Stan Strawbridge (Smith Lab) and Alisa Molotova (Franklin Lab) researchers Moyra Lawrence (Ghevaert Lab) and Will Bernard (Sinha Lab) took their first step into the world of science comedy. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Videos for Stem Cell Awareness Day |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Several Institute members participated in the series of videos for EuroStemCell as part of their campaign for Stem Cell Awareness Day. The videos were released on social media, sparking questions from the public, which were then addressed by the scientists. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Visit from MEP |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Vicky ford, MEP was interested in meeting to discuss the ECJ ruling on patents for Stem Cell Research Ms Ford has asked for a follow-up meeting. |
| Year(s) Of Engagement Activity | 2011 |
| Description | interview in Vienna Standard newspaper |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | interview in the Vienna Standard newspaper 3 July, 2013 n/a |
| Year(s) Of Engagement Activity | 2013 |